var title_f2_24_2432="Schistosome eggs";
var content_f2_24_2432=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Schistosome eggs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 187px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Gryseels, B, Polman, K, Clerinx, J, Kesten, J. Human schistosomiasis. Lancet 2006; 368:1106. Copyright &copy; 2006 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_24_2432=[""].join("\n");
var outline_f2_24_2432=null;
var title_f2_24_2433="Two causes for dry tap MRI";
var content_f2_24_2433=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance image of two causes for dry tap of knee: Lipoma arborescens and a gelatinous mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 304px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MR image showing two causes for potential failed arthrocentesis: Chronic synovial hypertrophy with fatty villous hypertrophy (lipoma arborescens, LA), and a nonenhancing gelatinous mass (G). Only placement of the needle into the enhancing fluid area (F, white arrow) would successfully yield fluid.",
"    <div class=\"footnotes\">",
"     M: medial; L: lateral.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Roberts WN, Hayes CW, Breitbach SA, et al. Am J Med 1996; 100:461.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_24_2433=[""].join("\n");
var outline_f2_24_2433=null;
var title_f2_24_2434="Actinic cheilitis 3";
var content_f2_24_2434=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Actinic cheilitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A focal area of scale is present on the patient's right lower lip.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_24_2434=[""].join("\n");
var outline_f2_24_2434=null;
var title_f2_24_2435="PCFCL chest";
var content_f2_24_2435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F73842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F73842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary cutaneous follicle center lymphoma with localized skin lesions on the chest",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_24_2435=[""].join("\n");
var outline_f2_24_2435=null;
var title_f2_24_2436="Bacitracin, neomycin, polymyxin B, and pramoxine: Patient drug information";
var content_f2_24_2436=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bacitracin, neomycin, polymyxin B, and pramoxine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32369?source=see_link\">",
"     see \"Bacitracin, neomycin, polymyxin B, and pramoxine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neosporin&reg; + Pain Relief Ointment [OTC];",
"     </li>",
"     <li>",
"      Tri Biozene [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to avoid or treat skin infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bacitracin, neomycin, polymyxin B, pramoxine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use longer than needed. A second infection may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697745",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care when putting on. Staining may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698190",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695952",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The treated part may be covered with a dressing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11134 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-E769C354BE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_24_2436=[""].join("\n");
var outline_f2_24_2436=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138848\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022500\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022499\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022504\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022505\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022507\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022502\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022503\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022508\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022509\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32369?source=related_link\">",
"      Bacitracin, neomycin, polymyxin B, and pramoxine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_24_2437="Technical aspects of thyroid ultrasound";
var content_f2_24_2437=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Technical aspects of thyroid ultrasound",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/24/2437/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/24/2437/contributors\">",
"     Manfred Blum, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/24/2437/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/24/2437/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/24/2437/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/24/2437/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/24/2437/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H26548118\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current methods of ultrasonography permit \"real-time\" identification of structures as small as 2 mm in diameter, thereby allowing the visualization of very small tumors of the thyroid and parathyroid glands. These methods also permit estimates of overall and regional blood flow to the thyroid. This topic review will discuss the basic technology of thyroid ultrasonography. The clinical use of thyroid ultrasonography is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=see_link\">",
"     \"Overview of the clinical utility of ultrasonography in thyroid disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26548248\">",
"    <span class=\"h1\">",
"     PRINCIPLES AND METHODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid ultrasonography is a technique that requires experience and an understanding of thyroid anatomy and pathology. It cannot be optimally performed by a technician who simply takes pictures and then submits the photographs for later interpretation. Instead, cost-effective testing requires input from both the clinician and the interpreting physician.",
"   </p>",
"   <p>",
"    Some endocrinologists prefer to perform the sonogram themselves, while others refer the patient to a sonographer or a radiologist. The endocrinologist or radiologist who does thyroid sonograms must acquire knowledge to perform the test and interpret the images, be willing to invest in costly and sophisticated equipment, and perform an adequate number of studies to achieve expertise. In addition, the ultrasound specialist and general radiologist must master thyroid palpation, anatomy and pathophysiology, and comprehend the specific clinical question posed; they cannot merely examine films or digital images. There is an increasing trend for endocrinologists to perform their own sonograms. No matter who does the test, results can sometimes be equivocal and misleading.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26548255\">",
"    <span class=\"h2\">",
"     Gray-scale ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gray-scale ultrasonography involves the intermittent generation of a pulse of sound energy and the reception of reflected echoes to produce an image of the structures traversed by the sound. Current technology produces high-resolution thyroid images by using sound frequencies between 5 and 13 million cycles per second (megahertz, MHz). These frequencies are well above the range audible by humans and are safe. Sound waves of this frequency pass through air poorly, and therefore the transducer, the device that generates the sound and receives the echo, must be coupled to the skin with a medium that excludes air.",
"   </p>",
"   <p>",
"    The sound waves penetrate tissues, and a portion of the energy is reflected at tissue interfaces up to a depth of 5 cm. The thyroid gland is well within this distance in most patients.",
"   </p>",
"   <p>",
"    Current transducers provide high resolution of structures as small as 2 mm, providing their echo-density is different or they are separated by an interface. In contrast, other imaging methods such as computed tomography, magnetic resonance imaging, and radionuclide scanning detect only nodules that are considerably larger, almost to the centimeter range.",
"   </p>",
"   <p>",
"    Some of the technical factors that limit the usefulness of ultrasonography include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Attenuation of the high-frequency sound waves in deeper tissues, which may make evaluation of very large goiters difficult",
"     </li>",
"     <li>",
"      Distortion by air-filled structures such as the trachea",
"     </li>",
"     <li>",
"      Blockade of the signals by calcific deposits in the thyroid, cartilage, or bone",
"     </li>",
"     <li>",
"      Nonvisualization of portions of the thyroid gland that lie substernally",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Images are best obtained with the patient lying supine with the neck hyper-extended. Care should be taken to avoid overextension in patients with limited range of motion in the neck. Landmarks such as the trachea, sternal notch, and the thyroid gland, and thyroid abnormalities should be carefully palpated and their locations noted. The entire region should be examined completely in the transverse plane, starting at the chin and extending to the sternal notch, and in the longitudinal (or &ldquo;sagittal&rdquo;) plane, starting in the midline and extending well laterally.",
"   </p>",
"   <p>",
"    A 5 to 7 MHz transducer often is used initially to determine the size of the thyroid gland and to assess the regional anatomy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60236 \" href=\"UTD.htm?24/6/24672\">",
"     image 1",
"    </a>",
"    ). Then higher energy transducers of 7.5 to 14 MHz are used to assess details such as nodules and vessels. There are protocols to assemble a mosaic of images to depict a very large thyroid lobe or goiter. A modification of conventional ultrasound, panoramic ultrasound, has been reported to produce images with a large anatomic field of view that displays both lobes of the thyroid gland on a single image [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2437/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 10 to 13 MHz transducer may be used to delineate nodules that are 2 to 3 mm in diameter. The value of detecting nodules of this size is debatable, as discussed below, because they are too small to aspirate for cytological examination, and their image may be difficult to reproduce. However, some information is obtained, notably the presence of microcalcifications, reproducible changes in size, or the emergence of a multinodular pattern.",
"   </p>",
"   <p>",
"    Doppler techniques can be added to differentiate cystic and vascular structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26548262\">",
"    <span class=\"h2\">",
"     Three-dimensional ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three-dimensional ultrasonography (3D) is a technical advance that promises to improve the analysis of anatomic structures and tumors relative to their environment and may enhance diagnosis as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26548269\">",
"    <span class=\"h2\">",
"     Color-flow Doppler ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Color-flow Doppler imaging is based upon the change in pitch (wave frequency) of a sound that increases when it approaches a listener (the ear or, in the case of ultrasonography, a transducer) and decreases as it departs. Doppler imaging provides information about blood flow to a static gray-scale image and, when superimposed on the real-time gray-scale image, indicates both the direction and the velocity of blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2437/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The assignment of color is designed to depict flow in opposite directions as red or blue to indicate arteries and veins. The shade of the color is a semiquantitative indicator of flow velocity. By convention, darker shades indicate slow flow and lighter shades high flow; black signifies no flow or an excessively oblique angle of the Doppler signal to the vascular structure. When viewed in the gray-scale mode, the Doppler flow signal is intensely bright.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26548276\">",
"    <span class=\"h2\">",
"     B-flow imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;B-flow ultrasonic imaging (BFI) is a non-Doppler technology that depicts motion within anatomic structures. Adjacent ultrasound beams, separated by a specified distance, are transmitted; the reflected signals, which are separated from each other by a shorter predetermined distance, are then detected; overlapping pairs of signals are then assembled and processed. The information correlates with motion, which in the thyroid is blood-flow. BFI may avoid artifacts that limit the value of Doppler imaging and thus supplement it.",
"   </p>",
"   <p>",
"    In addition, BFI may identify rapidly flashing bright spots, called \"twinkling,\" which seem to be generated by microcalcifications and may correlate with thyroid cancer. This was illustrated in a study of 479 nodules with histologic confirmation, the presence of four or more B-flow twinkling signs at a distance of greater than 2 mm was associated with 99.6 percent specificity and 65.2 percent sensitivity for papillary thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2437/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26548283\">",
"    <span class=\"h2\">",
"     Ultrasound contrast agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography is likely to improve when images are enhanced with contrast agents. One such agent involves gas-filled microbubbles with a mean diameter less than that of a red blood corpuscle injected intravenously [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2437/abstract/6\">",
"     6",
"    </a>",
"    ]. In one report, a galactose-based ultrasonographic contrast agent, Levovist (Schering AG, Berlin, Germany), showed promise in differentiating benign from malignant thyroid nodules. Cancers showed a significantly earlier arrival time of Levovist than nodular hyperplastic benign nodules and adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2437/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Similar results were seen with a different ultrasonographic contrast agent, sulphur-hexafluoride [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2437/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26548290\">",
"    <span class=\"h2\">",
"     Estimation of tissue elasticity by ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elastography examines the stiffness of tissue, which may correlate with the palpable consistency of anatomic structures. Using echography, one may infer the deformation of a tissue by observing change in Doppler signal in response to externally applied pressure or vibrations, or by tracking something called shear wave propagation. Investigators are gathering data about the elastic qualities of many different organs and tissues, including the thyroid, to assess the clinical diagnosis of benign and malignant conditions. Elastography may enhance the cancer-predictive value of sonography of non-cystic non-calcified thyroid nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2437/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26548600\">",
"    <span class=\"h1\">",
"     ESTIMATION OF THYROID GLAND VOLUME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid ultrasonography is used to answer questions about the size and anatomy of the thyroid gland and adjacent structures in the neck. Using two-dimensional images, a skilled ultrasonographer is able to reconstruct the thyroid in three dimensions. The structural information becomes optimally useful in management when it is integrated with other clinical data.",
"   </p>",
"   <p>",
"    Using a low frequency transducer, the dimensions of each lobe should be determined in the sagittal and transverse planes to determine the length (L), anterior-posterior depth (D), and transverse width (W) of the gland. The volume of the thyroid gland, lobe, or nodule can then be calculated using a simplified formula for a prolate ellipse:",
"   </p>",
"   <p>",
"    &nbsp;Volume &nbsp;= &nbsp;0.5 &nbsp;x &nbsp;(L &nbsp;x &nbsp;D &nbsp;x &nbsp;W)",
"   </p>",
"   <p>",
"    The size of a nodule or a lobe can be measured fairly accurately based on a scale on the sonographic screen or, with advanced equipment, the sonographer can place marks on the image to calculate the dimensions electronically. One study reported imperfect concordance between the dimensions of thyroid nodules as revealed by ultrasound examination when compared with surgical excision. Concordance was 78.5 percent with nodules equal to or smaller of than 1 cm and significantly less for larger nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2437/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Minimizing differences between ultrasonographers when estimating the size of large goiters or nodules has been reported when curved-array transducers rather than linear-array equipment is employed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2437/abstract/13\">",
"     13",
"    </a>",
"    ]. Accuracy in estimating volume becomes important when one uses ultrasound measurements to calculate an isotope dose, as an index of iodine intake in epidemiologic studies, or to compare size changes in a nodule over time. Using planimetry from three-dimensional images reportedly has lower intra-observer variability (3.4 percent) and higher repeatability (96.5 percent) than the standard ellipsoid model for nodules and lobes (14.4 percent variability and 84.8 percent repeatability) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2437/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, one must be especially cautious when interpreting reported changes in the volume of nodules based upon ultrasonic volume assessments because it is difficult to reproduce identical two-dimensional image planes for follow-up studies. The variation of ultrasonic thyroid nodule volume determinations among three ultrasonographers with certified experience in thyroid ultrasound was examined in a prospective blinded trial of 42 patients (8 men, 34 women) with 25 uninodular and 17 multinodular thyroid glands. The inter-observer variation for the determination of thyroid nodule volume (n = 38) was 48.96 percent for the ellipsoid method of assessing size and 48.64 percent for the planimetric method. Furthermore, the authors reported that a regression analysis revealed that the probability that all three sonographers would identify the same nodule in nodular thyroid glands was 90 percent, if the nodule is at least 15 mm in greatest diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2437/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The accuracy of thyroid volume assessment of thyroid volume and improved intra-observer variability and repeatability appears to be achieved with three-dimensional echography [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2437/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26548607\">",
"    <span class=\"h1\">",
"     CHARACTERIZATION OF THYROID NODULES",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-resolution ultrasonography provides a detailed map of thyroid nodules and helps to characterize the nodules. Solid nodules should be described by using normal thyroid tissue as a reference. Among solid nodules, the intensity of the echo pattern relative to the extranodular thyroid lobe depends upon the transmission or reflection of the ultrasonic signal by the nodule. Hypoechoic solid nodules transmit the sound energy with minimal reflection while hyperechoic nodules reflect a greater proportion of the signal. Isoechoic nodules interact with the ultrasound in the same way as normal thyroid tissue. The clinical use of ultrasound to identify and characterize nodules is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=see_link&amp;anchor=H26549334#H26549334\">",
"     \"Overview of the clinical utility of ultrasonography in thyroid disease\", section on 'Thyroid nodules'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26548781\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gray-scale ultrasonography involves the intermittent generation of a pulse of sound energy (sound frequencies between 5 and 13 million cycles per second [megahertz, MHz]) and the reception of reflected echoes to produce an image of the structures traversed by the sound. (See",
"      <a class=\"local\" href=\"#H26548255\">",
"       'Gray-scale ultrasonography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Current transducers provide high resolution of structures as small as 2 mm, providing their echo-density is different or they are separated by an interface. (See",
"      <a class=\"local\" href=\"#H26548255\">",
"       'Gray-scale ultrasonography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Color-flow Doppler imaging is based upon the change in pitch (wave frequency) of a sound that increases when it approaches a listener (the ear or, in the case of ultrasonography, a transducer) and decreases as it departs. Doppler imaging provides information about blood flow to a static gray-scale image and, when superimposed on the real-time gray-scale image, indicates both the direction and the velocity of blood flow. (See",
"      <a class=\"local\" href=\"#H26548269\">",
"       'Color-flow Doppler ultrasonography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      B-flow ultrasonic imaging (BFI) is a non-Doppler technology that depicts motion within anatomic structures. (See",
"      <a class=\"local\" href=\"#H26548276\">",
"       'B-flow imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thyroid ultrasonography is used to answer questions about the size and anatomy of the thyroid gland. The volume of the thyroid gland, lobe, or nodule can be calculated using the simplified formula for a prolate ellipse: Volume &nbsp;= &nbsp;0.5 &nbsp;x &nbsp;(L &nbsp;x &nbsp;D &nbsp;x &nbsp;W). (See",
"      <a class=\"local\" href=\"#H26548600\">",
"       'Estimation of thyroid gland volume'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2437/abstract/1\">",
"      Shapiro RS. Panoramic ultrasound of the thyroid. Thyroid 2003; 13:177.",
"     </a>",
"    </li>",
"    <li>",
"     Foley WD. Physical principles and instrumentation. In: Color Doppler Flow Imaging, Foley WD (Ed), Andover Medical Publishers, Boston 1991. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2437/abstract/3\">",
"      Clark KJ, Cronan JJ, Scola FH. Color Doppler sonography: anatomic and physiologic assessment of the thyroid. J Clin Ultrasound 1995; 23:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2437/abstract/4\">",
"      Brunese L, Romeo A, Iorio S, et al. A new marker for diagnosis of thyroid papillary cancer: B-flow twinkling sign. J Ultrasound Med 2008; 27:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2437/abstract/5\">",
"      Brunese L, Romeo A, Iorio S, et al. Thyroid B-flow twinkling sign: a new feature of papillary cancer. Eur J Endocrinol 2008; 159:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2437/abstract/6\">",
"      Jakobsen JA. Ultrasound contrast agents: clinical applications. Eur Radiol 2001; 11:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2437/abstract/7\">",
"      Spiezia S, Farina R, Cerbone G, et al. Analysis of color Doppler signal intensity variation after levovist injection: a new approach to the diagnosis of thyroid nodules. J Ultrasound Med 2001; 20:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2437/abstract/8\">",
"      Menna S, Di Virgilio MR, Burke P. [Ultrasonography contrast media Levovist and power Doppler in the study of the breast. Methodology, vascular morphology and automatic enhancement quantification with wash-in and wash-out curves]. Radiol Med 1999; 97:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2437/abstract/9\">",
"      Appetecchia M, Bacaro D, Brigida R, et al. Second generation ultrasonographic contrast agents in the diagnosis of neoplastic thyroid nodules. J Exp Clin Cancer Res 2006; 25:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2437/abstract/10\">",
"      Garra BS. Imaging and estimation of tissue elasticity by ultrasound. Ultrasound Q 2007; 23:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2437/abstract/11\">",
"      Rago T, Santini F, Scutari M, et al. Elastography: new developments in ultrasound for predicting malignancy in thyroid nodules. J Clin Endocrinol Metab 2007; 92:2917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2437/abstract/12\">",
"      Deveci MS, Deveci G, LiVolsi VA, et al. Concordance between thyroid nodule sizes measured by ultrasound and gross pathology examination: effect on patient management. Diagn Cytopathol 2007; 35:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2437/abstract/13\">",
"      Peeters EY, Shabana WM, Verbeek PA, Osteaux MM. Use of a curved-array transducer to reduce interobserver variation in sonographic measurement of thyroid volume in healthy adults. J Clin Ultrasound 2003; 31:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2437/abstract/14\">",
"      Lyshchik A, Drozd V, Reiners C. Accuracy of three-dimensional ultrasound for thyroid volume measurement in children and adolescents. Thyroid 2004; 14:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2437/abstract/15\">",
"      Brauer VF, Eder P, Miehle K, et al. Interobserver variation for ultrasound determination of thyroid nodule volumes. Thyroid 2005; 15:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2437/abstract/16\">",
"      Lyshchik A, Drozd V, Reiners C. Accuracy of three-dimensional ultrasound for thyroid volume measurement in children and adolescents. Thyroid 2004; 14:113.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15313 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.167.4.114-B39C775BF0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_24_2437=[""].join("\n");
var outline_f2_24_2437=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26548781\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26548118\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26548248\">",
"      PRINCIPLES AND METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26548255\">",
"      Gray-scale ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26548262\">",
"      Three-dimensional ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26548269\">",
"      Color-flow Doppler ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26548276\">",
"      B-flow imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26548283\">",
"      Ultrasound contrast agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26548290\">",
"      Estimation of tissue elasticity by ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26548600\">",
"      ESTIMATION OF THYROID GLAND VOLUME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26548607\">",
"      CHARACTERIZATION OF THYROID NODULES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26548781\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/15313\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/15313|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/6/24672\" title=\"diagnostic image 1\">",
"      Thyroid ultrasound showing thyroid anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=related_link\">",
"      Overview of the clinical utility of ultrasonography in thyroid disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_24_2438="Atenolol and chlorthalidone: Patient drug information";
var content_f2_24_2438=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Atenolol and chlorthalidone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/45/44758?source=see_link\">",
"     see \"Atenolol and chlorthalidone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F137732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tenoretic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F137733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Atenidone&reg;;",
"     </li>",
"     <li>",
"      Novo-Atenolthalidone;",
"     </li>",
"     <li>",
"      Tenoretic&reg;;",
"     </li>",
"     <li>",
"      Teva-Atenolol Chlorthalidone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not stop taking this drug all of a sudden. If you do, chest pain that is worse and in some cases heart attack may occur. The risk may be greater if you have certain types of heart disease. To avoid side effects, you will want to slowly stop this drug  as ordered by your doctor. Call your doctor right away if you have new or worse chest pain or if other heart problems occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to atenolol, chlorthalidone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703705",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Very bad kidney disease, very weak heart, or slow heartbeat without a working pacemaker.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11028 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9F1D191359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_24_2438=[""].join("\n");
var outline_f2_24_2438=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137732\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137733\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018482\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018484\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018483\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018488\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018489\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018491\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018486\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018487\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018492\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018493\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/45/44758?source=related_link\">",
"      Atenolol and chlorthalidone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_24_2439="Meropenem: Pediatric drug information";
var content_f2_24_2439=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Meropenem: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"    see \"Meropenem: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/47/40691?source=see_link\">",
"    see \"Meropenem: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F193322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Merrem&reg; I.V.",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F193323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Merrem&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Carbapenem",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Susceptible infection (non-CNS), treatment: For organisms highly susceptible to meropenem, MIC &lt;4 mcg/mL (Smith, 2011):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GA &lt;32 weeks:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     PNA &lt;14 days: 20 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     PNA &ge;14 days: 20 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GA &ge;32 weeks:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     PNA &lt;14 days: 20 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     PNA &ge;14 days: 30 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Moderately resistant infection (non-CNS), treatment: For organisms with MIC 4-8 mcg/mL: Limited data available; further studies needed: GA &gt;30 weeks, PNA &gt;7 days: 40 mg/kg/dose every 8 hours, some suggest as a 4-hour infusion; dosing based on a single-dose pharmacokinetic study (n=38) (van den Anker, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Meningitis:",
"     </b>",
"     Limited data available; optimal dose not established; further studies are needed. An evaluation of CSF concentrations in six patients using the dosing for susceptible infection  [see Susceptible infection (non-CNS) dosing]  reported levels to be above the target of 4 mcg/mL and highly variable (4.1-34.6 mcg/mL) at 0.3-7.9 hours (Smith, 2011); other suggest using the upper end of the dosing range (van den Anker, 2009); recommended duration of therapy dependent upon pathogen:",
"     <i>",
"      N. meningitides",
"     </i>",
"     ,",
"     <i>",
"      H. influenza:",
"     </i>",
"     7 days;",
"     <i>",
"      S. pneumoniae:",
"     </i>",
"     10-14 days;",
"     <i>",
"      Listeria monocytogenes:",
"     </i>",
"     &ge; 21 days; aerobic gram negative bacilli: Either 2 weeks beyond the first sterile CSF culture or &gt;3 weeks, whichever is longer (Tunkel, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"      see \"Meropenem: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants &lt;3 months:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Susceptible infection (non-CNS), treatment:",
"     </b>",
"     For organisms highly susceptible to meropenem, MIC &lt;4 mcg/mL: 20-30 mg/kg/dose every 8 hours (Smith, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Meningitis:",
"     </b>",
"     40 mg/kg/dose every 8 hours; duration of therapy dependent upon pathogen:",
"     <i>",
"      N. meningitides",
"     </i>",
"     ,",
"     <i>",
"      H. influenza",
"     </i>",
"     : 7 days;",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     : 10-14 days; aerobic gram-negative bacilli: 21 days;",
"     <i>",
"      Listeria monocytogenes",
"     </i>",
"     : &ge;21 days   (Tunkel, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants &ge;3 months, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Complicated skin and skin structure infection:",
"     </b>",
"     10 mg/kg/dose every 8 hours; maximum dose: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Intra-abdominal infection:",
"     </b>",
"     20 mg/kg/dose every 8 hours for 4-7 days; maximum dose: 1000 mg (Solomkin, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Meningitis:",
"     </b>",
"     40 mg/kg/dose every 8 hours; maximum dose: 2000 mg; duration of therapy dependent upon pathogen:",
"     <i>",
"      N. meningitides",
"     </i>",
"     ,",
"     <i>",
"      H. influenza:",
"     </i>",
"     7 days;",
"     <i>",
"      S. pneumoniae:",
"     </i>",
"     10-14 days; aerobic gram negative bacilli: 21 days (Tunkel, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Fever/neutropenia empiric treatment:",
"     </b>",
"     20 mg/kg/dose every 8 hours; maximum dose: 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Pulmonary exacerbation in patients with cystic fibrosis:",
"     </b>",
"     40 mg/kg/dose every 8 hours; maximum dose: 2000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Complicated skin and skin structure infection:",
"     </b>",
"     500 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Intra-abdominal infection:",
"     </b>",
"     1000 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Fever/neutropenia empiric treatment:",
"     </b>",
"     1000 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Meningitis:",
"     </b>",
"     2000 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GFR 30-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 20-40 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GFR 10-29 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 10-20 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GFR &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 10-20 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD): 10-20 mg/kg/dose every 24 hours; on dialysis days give dose",
"     <b>",
"      after",
"     </b>",
"     hemodialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peritoneal dialysis (PD): 10-20 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): 20-40 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     26-50 mL/minute: Standard dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-25 mL/minute: One-half dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: One-half dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alternative dosing recommendations (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GFR 10-50 mL/minute: Administer recommended dose (based on indication) every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GFR &lt;10 mL/minute: Administer recommended dose (based on indication) every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Meropenem and its metabolites are dialyzable: 500 mg every 24 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times/week, complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peritoneal dialysis: Administer recommended dose (based on indication) every 24 hours (Aronoff, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     CVVH: Loading dose of 1 g followed by either 0.5 g every 8 hours or 1 g every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     CVVHD/CVVHDF: Loading dose of 1 g followed by either 0.5 g every 6-8 hours or 1 g every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Consider giving patients receiving CVVHDF dosages of 750 mg every 8 hours or 1500 mg every 12 hours (Heintz, 2009). Substantial variability exists in various published recommendations, ranging from 1-3 g/day in 2-3 divided doses. One gram every 12 hours achieves a target trough of ~4 mg/L.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F193298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 500 mg, 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Merrem&reg; I.V.: 500 mg [contains sodium 45.1 mg as sodium carbonate (1.96 mEq)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Merrem&reg; I.V.: 1 g [contains sodium 90.2 mg as sodium carbonate (3.92 mEq)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F193283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1048508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by I.V. push or I.V. intermittent infusion; infuse I.V. push injection over 3-5 minutes at a final concentration not to exceed 50 mg/mL; intermittent infusion dose should be administered over 15-30 minutes at a final concentration ranging from 1-20 mg/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS; some studies have demonstrated enhanced pharmacodynamic effects when extending intermittent infusions to 4 hours (van den Anker, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F193369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS for 4 hours at controlled room temperature and up to 24 hours refrigerated;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, mannitol 2.5%, mannitol 10%, sodium bicarbonate 5%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aminophylline, anidulafungin, atropine, caspofungin, cimetidine, cyclosporine, dexamethasone sodium phosphate, digoxin, diphenhydramine, docetaxel, enalaprilat, fluconazole, furosemide, gentamicin, heparin, insulin (regular), linezolid, metoclopramide, milrinone, morphine, norepinephrine, phenobarbital, telavancin, vancomycin, vasopressin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B, diazepam, metronidazole, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Acyclovir, calcium gluconate, doxycycline, ondansetron, potassium chloride, zidovudine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible",
"     </b>",
"     with pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1048502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); meropenem reconstituted with SWI is stable for up to 2 hours at room temperature or for up to 12 hours when refrigerated; when reconstituted with NS to a final concentration between 2.5-50 mg/mL, the solution is stable for up to 2 hours at room temperature or 18 hours when refrigerated; when reconstituted with D",
"     <sub>",
"      5",
"     </sub>",
"     W to a final concentration between 2.5-50 mg/mL, the solution is stable for up to 1 hour at room temperature or 8 hours when refrigerated; solutions prepared for infusion in plastic I.V. bags with NS at concentrations ranging from 2.5-20 mg/mL are stable for 4 hours at room temperature or 24 hours when refrigerated",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of multidrug-resistant infection caused by gram-negative and gram-positive aerobic and anaerobic pathogens documented or suspected to be susceptible to meropenem; used in treatment of meningitis (FDA approved in pediatric patients ages &ge;3 months), intra-abdominal infections and complicated skin and skin structure infections caused by susceptible",
"     <i>",
"      S. aureus",
"     </i>",
"     ,",
"     <i>",
"      S. pyogenes",
"     </i>",
"     ,",
"     <i>",
"      S. agalactiae",
"     </i>",
"     ,",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      N. meningitidis",
"     </i>",
"     ,",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     ,",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      Klebsiella",
"     </i>",
"     ,",
"     <i>",
"      Enterobacter",
"     </i>",
"     ,",
"     <i>",
"      Serratia",
"     </i>",
"     ,",
"     <i>",
"      P. aeruginosa",
"     </i>",
"     ,",
"     <i>",
"      B. cepacia",
"     </i>",
"     , and",
"     <i>",
"      B. fragilis",
"     </i>",
"     (FDA approved in ages &ge;3 months and adults); has been used for treatment of lower respiratory tract infections, acute pulmonary exacerbations in cystic fibrosis, urinary tract infections, empiric treatment of febrile neutropenia, and sepsis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6027563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Meropenem may be confused with ertapenem, imipenem, metroNIDAZOLE",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F193368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash (includes diaper-area moniliasis in infants)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, glossitis, nausea, oral moniliasis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Inflammation at the injection site, injection site reaction, phlebitis/thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, pharyngitis, pneumonia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Sepsis, shock",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal enlargement, abdominal pain, agitation/delirium, agranulocytosis, alkaline phosphatase increased, ALT increased, AST increased, anemia (hypochromic), angioedema, anorexia, anxiety, aPTT decreased, asthma, back pain, bilirubin increased, bradycardia, BUN increased, cardiac arrest, chest pain, chills, cholestatic jaundice/jaundice, confusion, cough, creatinine increased, depression, diaphoresis, dizziness, dyspepsia, dyspnea, dysuria, eosinophilia, epistaxis, erythema multiforme, fever, flatulence, gastrointestinal hemorrhage, hallucinations, heart failure, hematuria, hemoglobin/hematocrit decreased, hemolytic anemia, hemoperitoneum, hepatic failure, hyper-/hypotension, hypervolemia, hypokalemia, hypoxia, ileus, injection site edema, injection site pain, insomnia, intestinal obstruction, LDH increased, leukocytosis, leukopenia, melena, MI, nervousness, neutropenia, paresthesia, pelvic pain, peripheral edema, platelets decreased/increased, pleural effusion, PT decreased, pulmonary edema, positive Coombs test, pulmonary embolism, renal failure, respiratory disorder, seizure, skin ulcer, somnolence, Stevens-Johnson syndrome, syncope, tachycardia, toxic epidermal necrolysis, urinary incontinence, urticaria, vaginal moniliasis, weakness, WBC decreased, whole body pain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to meropenem, any component, other carbapenems, or in patients who have experienced anaphylactic reactions to beta-lactams",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1048497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with a history of seizures, CNS disease, CNS infection, and/or compromised renal function; dosage adjustment required in patients with renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1048496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious and occasionally fatal hypersensitivity reactions have been reported in patients receiving beta-lactam therapy; careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, or other beta-lactams before initiating meropenem.  Pseudomembranous colitis has been reported with the use of meropenem; prolonged use may result in superinfection. Seizures and other CNS adverse events have been reported, most commonly in patients with renal impairment and/or underlying neurologic disorders. Valproic acid (VPA) serum concentrations may be significantly decreased by concurrent carbapenem use leading to breakthrough seizures; serum VPA concentrations should be closely monitored after initiation of meropenem.  VPA dosage adjustment may not adequately compensate for this interaction. Thrombocytopenia has been reported in patients with renal dysfunction who are receiving meropenem.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F193292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Carbapenems may decrease the serum concentration of Divalproex.  Management: Concurrent use of carbapenem antibiotics with divalproex is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Meropenem.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Carbapenems may decrease the serum concentration of Valproic Acid.  Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F193294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F193307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Incomplete transplacental transfer of meropenem was found using an",
"     <i>",
"      ex vivo",
"     </i>",
"     human perfusion model.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1048504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic renal, hepatic, and hematologic function tests. Observe for changes in bowel frequency.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1048495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs) with its strongest affinities for PBPs 2, 3 and 4 of",
"     <i>",
"      E. coli",
"     </i>",
"     and",
"     <i>",
"      P. aeruginosa",
"     </i>",
"     and PBPs 1, 2 and 4 of",
"     <i>",
"      S. aureus",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1048510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Penetrates into most tissues and body fluids including urinary tract, peritoneal fluid, bone, bile, lung, bronchial mucosa, muscle tissue, heart valves, and CSF (CSF penetration: Neonates and Infants &le;3 months: 70%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates and Infants &le;3 months: Median: ~0.47 L/kg (Smith, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 0.3-0.4 L/kg (Blumer, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 15-20 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 2%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: 20% is hydrolyzed in plasma to an inactive metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates and Infants &le;3 months: Median: 2.7 hours; range: 1.6- 3.8 hours (Smith, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children 3 months to 2 years: 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-12 years and Adults: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak tissue and fluid concentrations: 1 hour after the start of infusion except in bile, lung, muscle, and CSF which peak at 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Cleared by the kidney with 70% excreted unchanged in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates and Infants &le;3 months: 0.12 L/hour/kg (Smith, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children: 0.26-0.37 L/hour/kg (Blumer, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Meropenem and metabolite readily dialyzable",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10135185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/47/40691?source=see_link\">",
"      see \"Meropenem: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inform physician if taking valproic acid or divalproex sodium since an alternative treatment may be needed; inform physician of prolonged diarrhea.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1048512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium content 1 g: 3.92 mEq",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007, 61, 97, 153, 177.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blumer JL, Saiman L, Konstan MW, et al, \"The Efficacy and Safety of Meropenem and Tobramycin Vs Ceftazidime and Tobramycin in the Treatment of Acute Pulmonary Exacerbations in Patients With Cystic Fibrosis,\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2005, 128(4):2336-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/24/2439/abstract-text/16236892/pubmed\" id=\"16236892\" target=\"_blank\">",
"        16236892",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blummer JL, &ldquo;Pharmacokinetic Determinants of Carbapenem Therapy in Neonates and Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1996, 15(8):733-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/24/2439/abstract-text/8858691/pubmed\" id=\"8858691\" target=\"_blank\">",
"        8858691",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blummer JL, Reed MD, Kearns GL, et al, &ldquo;Sequential, Single-Dose Pharmacokinetic Evaluation of Meropenem in Hospitalized Infants and Children,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1995, 39(8):1721-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/24/2439/abstract-text/7486908/pubmed\" id=\"7486908\" target=\"_blank\">",
"        7486908",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley, JS, &ldquo;Meropenem: A New, Extremely Broad Spectrum Beta-lactam Antibiotic for Serious Infections in Pediatrics,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1997, 16:263-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/24/2439/abstract-text/9076812 /pubmed\" id=\"9076812 \" target=\"_blank\">",
"        9076812",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Sauberan JB, Ambrose PG, et al, \"Meropenem Pharmacokinetics, Pharmacodynamics, and Monte Carlo Simulation in the Neonate,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2008, 27(9):794-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/24/2439/abstract-text/18645546/pubmed\" id=\"18645546\" target=\"_blank\">",
"        18645546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Craig WA, &ldquo;The Pharmacology of Meropenem, a New Carbapenem Antibiotic,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1997, 24(Suppl 2):266-75.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, and Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/24/2439/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Latzin P, Fehling M, Bauernfeind A, et al, \"Efficacy and Safety of Intravenous Meropenem and Tobramycin Versus Ceftazidime and Tobramycin in Cystic Fibrosis,\"",
"      <i>",
"       J Cyst Fibros",
"      </i>",
"      , 2008, 7(2):142-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/24/2439/abstract-text/17766190/pubmed\" id=\"17766190\" target=\"_blank\">",
"        17766190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Odio CM, Puig JR, Feris JM, et al, &ldquo;Prospective, Randomized, Investigator-Blinded Study of the Efficacy and Safety of Meropenem vs. Cefotaxime Therapy in Bacterial Meningitis in Children. Meropenem Meningitis Study Group,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1999, 18(7):581-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/24/2439/abstract-text/10440432/pubmed\" id=\"10440432\" target=\"_blank\">",
"        10440432",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith PB, Cohen-Wolkowiez M, Castro LM, et al, &ldquo;Populations Pharmacokinetics of Meropenem in Plasma and Cerebrospinal Fluid of Infants With Suspected or Complicated Intra-abdominal Infections, \"Pediatr Infect Dis J,\" 2011, 30(10):844-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, \"Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/24/2439/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, \"Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/24/2439/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al, \"Practice Guidelines for the Management of Bacterial Meningitis,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2004, 39(9):1267-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/24/2439/abstract-text/15494903/pubmed\" id=\"15494903\" target=\"_blank\">",
"        15494903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Anker JN, Pokorna P, Kinzig-Schippers M, et al, \"Meropenem Pharmacokinetics in the Newborn,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2009, 53(9):3871-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/24/2439/abstract-text/19581463/pubmed\" id=\"19581463\" target=\"_blank\">",
"        19581463",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ververs TF, van Dijk A, Vinks SA, et al, &ldquo;Pharmacokinetics and Dosing Regimen of Meropenem in Critically Ill Patients Receiving Continuous Venovenous Hemofiltration,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2000, 28(10):3412-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/24/2439/abstract-text/11057794/pubmed\" id=\"11057794\" target=\"_blank\">",
"        11057794",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiseman LR, Wagstaff AJ, Brogden RN, et al, &ldquo;Meropenem. A Review of its Antibacterial Activity, Pharmacokinetic Properties and Clinical Efficacy,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1995, 50(1):73-101.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/24/2439/abstract-text/7588092/pubmed\" id=\"7588092\" target=\"_blank\">",
"        7588092",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yildirim I, Aytac S, Ceyhan M, et al, \"Piperacillin/Tazobactam Plus Amikacin Versus Carbapenem Monotherapy as Empirical Treatment of Febrile Neutropenia in Childhood Hematological Malignancies,\"",
"      <i>",
"       Pediatr Hematol Oncol",
"      </i>",
"      , 2008, 25(4):291-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/24/2439/abstract-text/18484473/pubmed\" id=\"18484473\" target=\"_blank\">",
"        18484473",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12583 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5917900B73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_24_2439=[""].join("\n");
var outline_f2_24_2439=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193322\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193323\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048505\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443862\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048498\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193298\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193283\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048508\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193369\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048502\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048507\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027563\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193368\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048511\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048497\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048496\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299674\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193292\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193294\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193307\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048504\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048495\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048510\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10135185\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048512\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12583\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12583|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=related_link\">",
"      Meropenem: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/47/40691?source=related_link\">",
"      Meropenem: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_24_2440="Forceps of aftercoming head 1";
var content_f2_24_2440=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57167%7EOBGYN%2F68911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57167%7EOBGYN%2F68911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Forceps applied to after-coming head",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The head has entered the pelvis and forceps have been applied.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pritchard, JA, MacDonald, PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright &copy;1980 McGraw Hill. p.1071.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Forceps delivery of after-coming head",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pritchard, JA, MacDonald, PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright &copy;1980 McGraw Hill. p.1071.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_24_2440=[""].join("\n");
var outline_f2_24_2440=null;
var title_f2_24_2441="Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients";
var content_f2_24_2441=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/24/2441/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/24/2441/contributors\">",
"     David E Griffith, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/24/2441/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/24/2441/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/24/2441/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/24/2441/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/24/2441/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of nontuberculous mycobacterial (NTM) infection of the lung, as in other body sites, is dependent upon the species of the infecting organism. The three most common pulmonary syndromes due to NTM are caused by M. avium complex (MAC), M. kansasii, and M. abscessus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the past, NTM were commonly believed to be laboratory contaminants or to colonize airways without causing disease. However, it has become evident that prolonged (more than two weeks) airway colonization with no histopathologic host response is uncommon in symptomatic patients who are undergoing diagnostic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. On the other hand, low numbers of organisms that are recovered from single specimens may not be the major cause of the patient's symptoms and may clear without antimicrobial drugs. Furthermore, disease may range in severity from subclinical or low-grade infection to extensive destruction of the lungs. Patients who are immunocompromised by virtue of AIDS, hemolymphatic malignancies, or immunosuppressive drugs have a much greater tendency to develop disseminated disease than immunologically intact individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More effective drugs are needed for the treatment of NTM, and it is hoped that better agents will emerge given the recent interest in developing more effective antituberculosis drugs, which has been stimulated by the need for improved therapy of drug-resistant tuberculosis.",
"   </p>",
"   <p>",
"    The treatment of NTM pulmonary infection will be reviewed here. The diagnosis, clinical manifestations, and microbiology of NTM infection, infection due to rapidly growing mycobacterium, and infection with M. marinum and M. ulcerans are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11045?source=see_link\">",
"     \"Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24759?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=see_link\">",
"     \"Microbiology of nontuberculous mycobacteria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5530?source=see_link\">",
"     \"Rapidly growing mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of presumed NTM infection is indicated in patients with the following findings (",
"    <a class=\"graphic graphic_table graphicRef61404 \" href=\"UTD.htm?10/48/11020\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compatible respiratory or constitutional symptoms with radiographic abnormalities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PLUS EITHER",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consistent isolation of NTM in moderate to high numbers from more than one specimen of pulmonary secretions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    OR",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isolation from at least one specimen if there is histologic evidence of pulmonary parenchymal involvement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other etiologies are presumed to be excluded by thorough evaluation. The diagnosis of nontuberculous pulmonary infections is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11045?source=see_link\">",
"     \"Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in any patient, the decision to treat is made by weighing the anticipated risks and benefits of therapy. Mitigating factors might include concurrent end-stage disease such as metastatic cancer or hepatic failure, mild or equivocal symptoms, previous or current adverse experience with the drugs, or the isolation of an isolate that is rarely pathogenic such as M. simiae, M. fortuitum, M. terrae complex, or M. chelonae. On the other hand, the immune status of the host must also be considered, since isolates that are usually non-pathogenic may be pathogenic in immunocompromised hosts. Close observation (eg, monthly) is indicated if the decision is made not to treat.",
"   </p>",
"   <p>",
"    Chemotherapy of NTM disease in different patient groups (eg, immunocompromised versus immunologically intact) is similar since the repertoire of effective drugs is limited. In each case, long-term management consists of bacteriologic surveillance, managing drug toxicity, and managing comorbidity. The degree of comorbidity may differ substantially between the different patient groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MYCOBACTERIUM AVIUM COMPLEX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycobacterium avium complex (MAC) is the most common pulmonary pathogen among this group of organisms in the United States. The newer macrolides have had a significant impact on the treatment of this disease. Prior to the advent of these agents, treatment with multidrug regimens, usually including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    , achieved initial sputum conversion rates of only 50 to 70 percent, with 20 to 30 percent relapse rates [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/2,8-10\">",
"     2,8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies of the newer macrolides for MAC have focused on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    . One study demonstrated that monotherapy with clarithromycin in a dose of 500 mg twice daily converted sputum cultures to negative in four months in approximately 60 percent of HIV-negative patients with chronic lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/11\">",
"     11",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    was somewhat less effective in a similar study [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    is effective as monotherapy, subsequent studies on selection and emergence of drug-resistant bacteria have shown that macrolides should not be given alone [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/11,13,14\">",
"     11,13,14",
"    </a>",
"    ]. The most potent and tolerable combination regimen has yet to be determined in randomized clinical trials in HIV-negative patients.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     Rifabutin",
"    </a>",
"    is more active in vitro than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    against MAC and is the preferred drug in HIV-positive patients due to drug-drug interactions between rifampin and antiretroviral drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Susceptibility testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Susceptibility testing of new culture isolates is currently recommended on a routine basis for macrolides (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ) only [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/2\">",
"     2",
"    </a>",
"    ]. Typical minimum inhibitory concentrations (MICs) for clarithromycin are 1 to 4",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    but under selective pressure of macrolide therapy, mutations in the drug's ribosomal binding site can result in MICs above 64",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. There is no proven value (ie, correlation between in vitro susceptibility and clinical or in vivo response) for in vitro susceptibility testing for antimycobacterial agents other than the macrolides for MAC.",
"   </p>",
"   <p>",
"    Susceptibility testing to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    is also useful for patients who do not respond to therapy within six months or who relapse after completion of therapy. The aim is to determine whether these agents should continue to be included in a multidrug regimen (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Recommended regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no randomized comparative trials of treatment for pulmonary disease caused by MAC in HIV-negative patients. Treatment recommendations are based on nonrandomized but controlled trials of macrolide-containing treatment regimens in HIV-negative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/11,12,18-21\">",
"     11,12,18-21",
"    </a>",
"    ], trials in HIV-positive patients, and the clinical experience of experts.",
"   </p>",
"   <p>",
"    The 2007",
"    <span class=\"nowrap\">",
"     ATS/IDSA",
"    </span>",
"    guidelines recommend the following regimen for the treatment of MAC nodular or bronchiectatic pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      (1000 mg three times per week) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (500 mg three times per week) PLUS",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"      (600 mg three times per week) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      (300 mg three times per week) PLUS",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       Ethambutol",
"      </a>",
"      (25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      three times per week)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with fibrocavitary MAC lung disease or severe nodular or bronchiectatic disease, the",
"    <span class=\"nowrap\">",
"     ATS/IDSA",
"    </span>",
"    guidelines recommend the following regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      (500 to 1000 mg daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (250 mg daily) PLUS",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"      (600 mg daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      (150 to 300 mg daily) PLUS",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       Ethambutol",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with fibrocavitary MAC lung disease or severe nodular or bronchiectatic disease, consideration should also be given to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    (both 10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    three times per week) as a fourth agent for the first eight weeks. The dose should be lowered to 6 to 8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    two to three times weekly for in patients who are older than 50 years of age, whose weight is &lt;50 kg, or who require parenteral therapy for longer than two to three months.",
"   </p>",
"   <p>",
"    Lower doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (eg, 500 mg once daily) may be necessary in patients over the age of 60 years who have a low body mass, especially if the creatinine clearance is reduced. In these patients, regular doses may lead to high drugs levels, which may be associated with intolerable side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     Streptomycin",
"    </a>",
"    is particularly useful in patients who have a substantial burden of extracellular organisms, against which streptomycin is highly active. Included in this group are patients with radiographically extensive or cavitary disease, particularly with strongly positive sputum smears. The streptomycin dose needs to be adjusted based upon age, weight, and renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experience with these regimens suggests that long-term sputum conversion rates up to 90 percent may be expected in patients in whom there is no history of previous treatment failure with these agents and who are able to tolerate all three oral drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. For unclear reasons, patients who have failed previous therapy, even with macrolide susceptible MAC isolates are less likely to respond to subsequent therapeutic efforts.",
"   </p>",
"   <p>",
"    Experience is accumulating with thrice weekly dosing of the four drugs, which suggests that intermittent dosing may be as effective as daily therapy and better tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. However, data suggests that intermittent medication dosing is not effective for patients with severe or cavitary disease or patients who have failed previous therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    (250",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or 500 mg three times per week) can be substituted for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    . In this setting,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    can be given in a dose of 150 to 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or 300 mg three times per week. Clarithromycin interacts with rifabutin to increase rifabutin levels, while azithromycin does not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Macrolide-resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients whose isolates become macrolide-resistant, parenteral agents including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    , should be considered. However, these drugs should be administered under the supervision of physicians experienced with their use because of the high incidence of potentially serious adverse effects. Other agents such as fluoroquinolones, clofazimine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"     cycloserine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"     ethionamide",
"    </a>",
"    , are sometimes used but are of unproven value.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     Pyrazinamide",
"    </a>",
"    is not active against MAC.",
"   </p>",
"   <p>",
"    Macrolide-resistant MAC lung disease is associated with a very poor prognosis in general. Data suggests that successful therapy of this condition requires both the use of parenteral drugs and surgical resection of involved lung tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should be continued until sputum cultures are consecutively negative for at least one year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86941664\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug toxicity should be monitored monthly. The following complications can occur:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrointestinal intolerance &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"     </li>",
"     <li>",
"      Abnormal liver function tests &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"     </li>",
"     <li>",
"      Low white blood cell count &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"     </li>",
"     <li>",
"      Impaired visual acuity and color vision &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"     </li>",
"     <li>",
"      Decreased auditory function &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"     </li>",
"     <li>",
"      Decreased renal function &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"     </li>",
"     <li>",
"      Peripheral neuropathy &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Decisions on dose modifications or drug discontinuations in the setting of toxicity are complex and depend on the type and severity of the toxicity and the importance of the offending drug in the patient&rsquo;s regimen. The threshold to discontinue a macrolide because of mild or moderate transaminitis is generally higher than that for discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    in the setting of objective visual deficits. Consultation with an expert in MAC treatment is advised in such situations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86941713\">",
"    <span class=\"h3\">",
"     Monitoring for clinical response",
"    </span>",
"    &nbsp;&mdash;&nbsp;We typically obtain sputum cultures monthly to monitor treatment efficacy. The likelihood of conversion to negative cultures is unlikely within the first few months of therapy. However, earlier documentation of sputum conversion allows optimization of treatment duration, which is based on the length of time with negative cultures (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Duration of therapy'",
"    </a>",
"    above). &nbsp;",
"   </p>",
"   <p>",
"    Lack of microbiological response after six months of therapy warrants evaluation for adherence to the drug regimen and susceptibility testing for macrolides. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Susceptibility testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86941720\">",
"    <span class=\"h3\">",
"     Therapeutic drug monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is minimal clinical evidence that monitoring drug levels and optimizing dosage affects the therapeutic outcome. In a pharmacokinetic analysis of drug levels among 481 patients undergoing macrolide-based multidrug therapy for MAC lung disease, suboptimal levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    were common,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    further decreased macrolide levels, and pharmacodynamic indices infrequently predicted bactericidal activity for most agents [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/25\">",
"     25",
"    </a>",
"    ]. However, the clinical meaningfulness of the minimum inhibitory concentration (on which target drug levels are based) of non-macrolide drugs for MAC is uncertain, and this study did not evaluate the correlation between drug levels and clinical response [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/26\">",
"     26",
"    </a>",
"    ]. Furthermore, in a separate study of 101 patients with MAC lung disease treated with a clarithromycin-based multidrug regimen, there was no difference in peak plasma drug levels between those with (n = 75) and without (n = 26) microbiological response after 12 months, even though almost all the patients had clarithromycin levels below the target range [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/27\">",
"     27",
"    </a>",
"    ]. Additionally, the general lack of correlation between in vitro indices and in vivo responses for agents other than macrolides limits the clinical implications of measured drug levels [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/26\">",
"     26",
"    </a>",
"    ]. Until further clinical data suggest otherwise, we do not routinely obtain therapeutic drug monitoring levels during therapy for MAC lung disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Surgical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung resection may play a role in the treatment of some patients with MAC lung disease. When surgery was initially proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/28\">",
"     28",
"    </a>",
"    ], drug treatment was much less effective and more surgeons were experienced with this type of surgery. At present, medical management should be considered the first line of management [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgery may be useful in the following settings and is generally effective in controlling infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/29-34\">",
"     29-34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with localized disease, especially upper lobe cavitary disease",
"     </li>",
"     <li>",
"      Patients in whom drugs fail to convert the sputum cultures to negative after six months of continuous treatment",
"     </li>",
"     <li>",
"      Patients who cannot tolerate medical therapy",
"     </li>",
"     <li>",
"      Patients with macrolide-resistant MAC lung disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lobectomy can be considered in patients with anatomically limited disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], while pneumonectomy may be required for patients with multiple cavitary lesions or a unilateral destroyed lung [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Bronchopleural fistula formation can complicate pneumonectomy, even with the use of pedicle flap closure, and is more common on the right side [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15400?source=see_link\">",
"     \"Preoperative evaluation for lung resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MYCOBACTERIUM KANSASII",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycobacterium kansasii is the second most common NTM causing pulmonary disease. There have been no randomized comparative trials of treatment for disease caused by M kansasii, comparing one drug regimen with another or with no drug treatment at all.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Thoracic Society recommendation for treatment of this infection consists of a three-drug combination consisting of [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       Isoniazid",
"      </a>",
"      (300 mg daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"      (600 mg daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       Ethambutol",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A prospective trial of 28 patients compared treatment with 12 or 18 month with this three-drug regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/35\">",
"     35",
"    </a>",
"    ]. Only one relapse occurred; the patient was in the 12-month chemotherapy group.",
"   </p>",
"   <p>",
"    The newer macrolides have not been extensively studied for the treatment of M. kansasii. However, the low MICs and efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    against other nontuberculous mycobacteria suggest that these drugs may have an important role in treating this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/11,36-38\">",
"     11,36-38",
"    </a>",
"    ]. A small prospective study of 18 patients has shown that a thrice-weekly clarithromycin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    containing regimen is effective, with no relapses during a mean follow-up of 46 months [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fluoroquinolone",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    , also has good in vitro activity against M. kansasii [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     Isoniazid",
"    </a>",
"    is less active against M. kansasii than it is against M. tuberculosis. Thus, the triad of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (500 mg twice daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    may be a reasonable alternative for patients unable to tolerate isoniazid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Rifampin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    resistance has been described in patients being treated for M. kansasii, especially those infected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/17,43\">",
"     17,43",
"    </a>",
"    ]. Higher doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    (900",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    have been used to treat these infections with approximately 90 percent success rates [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/43\">",
"     43",
"    </a>",
"    ]. The newer macrolides, the fluoroquinolone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"     ethionamide",
"    </a>",
"    , and streptomycin are other alternative agents.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    has good in vitro activity (MIC range &le;0.25-2",
"    <span class=\"nowrap\">",
"     microgram/mL)",
"    </span>",
"    but there is no clinical experience in treating M. kansasii disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/42,44\">",
"     42,44",
"    </a>",
"    ]. Our initial regimen in these patients consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , ethambutol, and isoniazid, with or without trimethoprim-sulfamethoxazole.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Treatment duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy is given for a minimum of 12 months of culture negativity. In a case series of 56 adults with M. kansasii pulmonary infection in Israel diagnosed in the time period 1999 to 2004, the mean duration of treatment was 21 &plusmn; 7 months [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/45\">",
"     45",
"    </a>",
"    ]. There were no disease-related deaths.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OTHER NONTUBERCULOUS MYCOBACTERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other slowly growing NTM, including M. szulgai, M. xenopi, M. simiae, and M. malmoense, can also cause chronic lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/46\">",
"     46",
"    </a>",
"    ]. It is difficult to make generalities about the therapy of disease caused by these organisms because there have been few randomized trials for the treatment of most of these organisms and none that have utilized highly effective medications. In addition, for most of these organisms, there is not a demonstrable correlation between in vitro susceptibility to a specific drug and in vivo response. As with MAC, more effective drugs are needed to improve outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Mycobacterium malmoense",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective case series of 106 patients with M. malmoense lung disease was collected over a five-year period by the British Thoracic Society (BTS) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/47\">",
"     47",
"    </a>",
"    ]. Two years of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    was equivalent to rifampin, ethambutol plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/10\">",
"     10",
"    </a>",
"    ], although only 53 percent of patients were alive at five years and 44 of the original 106 patients (42 percent) were cured of the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/47\">",
"     47",
"    </a>",
"    ]. In a follow-up study, the BTS randomly assigned 167 patients with M. malmoense lung disease to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , rifampin, and ethambutol, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , rifampin, and ethambutol. Overall response rates were low, but the group receiving clarithromycin had slightly better clinical responses and lower mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mycobacterium xenopi",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an uncontrolled retrospective study of 136 patients with pulmonary infection caused by M. xenopi, the absence of treatment was associated with a poor prognosis; median survival was 10 months in untreated patients compared with 32 months in treated patients (hazard ratio 3.0, 95% CI 1.94-4.74) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/49\">",
"     49",
"    </a>",
"    ]. Combination therapy with a rifamycin-containing regimen was associated with improved survival (hazard ratio 0.325, 95% CI 0.15-0.72). Since these outcomes were not adjusted for comorbidity, the difference in survival cannot be definitively attributed to treatment.",
"   </p>",
"   <p>",
"    In a similar study from the Netherlands, multiple different treatment regimens were used in 49 patients with M. xenopi lung disease, but no specific drug combination showed consistently superior results [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Mycobacterium szulgai",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary M. szulgai disease is rare, but M. szulgai isolates are usually clinically significant. Disease occurs most commonly in patients with underlying lung disease. In a study that included 12 patients who were treated for M. szulgai infection, patients responded well to multiple treatment regimens, usually including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    , and either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/51\">",
"     51",
"    </a>",
"    ]. Patients with M. szulgai lung disease appear more likely to respond to therapy than patients with M. malmoense, M. xenopi, or M. simiae infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Mycobacterium simiae",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. simiae, when isolated in clinical samples, is more often a contaminant than a true pathogen. When it is a true pathogen, however, it is extremely difficult to treat effectively. To date, although many regimens have been tried, there are no predictably effective drug combinations for treating M. simiae [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2441/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Rapidly growing mycobacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. fortuitum, M. abscessus, and M. chelonae are classified as rapidly growing mycobacteria (RGM) since they will grow in subculture within one week. The treatment of RGM pulmonary disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5530?source=see_link\">",
"     \"Rapidly growing mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The three most common pulmonary syndromes due to nontuberculous mycobacterium are caused by M. avium complex (MAC), M. kansasii, and M. abscessus. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of NTM infection is indicated in patients with compatible respiratory or constitutional symptoms, radiographic abnormalities, and isolation of NTM from pulmonary specimens that meet ATS diagnostic criteria (",
"      <a class=\"graphic graphic_table graphicRef61404 \" href=\"UTD.htm?10/48/11020\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend a combination of two to four drugs (as tolerated) for treatment of MAC pulmonary infection in HIV-negative patients (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Recommended regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest continuing treatment for MAC until sputum cultures are consecutively negative for at least one year (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients receiving MAC treatment should have monthly monitoring for drug toxicity and sputum cultures. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lung resection may play a role in the treatment of some patients with MAC lung disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Surgical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend a combination of three drugs for treatment of M. kansasii pulmonary infection in HIV-negative patients (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest continuing therapy for M. kansasii for a minimum of 12 months of culture negativity (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with M. szulgai, M. malmoense, and M. xenopi, there is no correlation between in vitro susceptibilities of individual drugs and in vivo response. For patients with disease caused by these pathogens, we suggest a multidrug treatment regimen including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      with or without INH (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). New therapeutic approaches are needed. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Other nontuberculous mycobacteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      M. simiae, when isolated in clinical samples, is more often a contaminant than a true pathogen. When it is a true pathogen, however, it is extremely difficult to treat effectively. To date, although many regimens have been tried, there are no predictably effective drug combinations for treating M. simiae. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Mycobacterium simiae'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/1\">",
"      Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 1979; 119:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/2\">",
"      Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/3\">",
"      Wallace RJ Jr. Mycobacterium avium complex lung disease and women. Now an equal opportunity disease. Chest 1994; 105:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/4\">",
"      Wolinsky E. When is an infection disease? Rev Infect Dis 1981; 3:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/5\">",
"      Horsburgh CR Jr, Mason UG 3rd, Farhi DC, Iseman MD. Disseminated infection with Mycobacterium avium-intracellulare. A report of 13 cases and a review of the literature. Medicine (Baltimore) 1985; 64:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/6\">",
"      Akiyama H, Maruyama T, Uetake T, et al. Systemic infection due to atypical mycobacteria in patients with chronic myelogenous leukemia. Rev Infect Dis 1991; 13:815.",
"     </a>",
"    </li>",
"    <li>",
"     Cegielski JP, Wallace RJ Jr. Nontuberculous mycobacterial infections of the central nervous system. In: Infections of the Central Nervous System, Scheld WM, Whitley RJ, Durack DT (Eds), Lippincott-Raven, New York 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/8\">",
"      Davidson PT, Khanijo V, Goble M, Moulding TS. Treatment of disease due to Mycobacterium intracellulare. Rev Infect Dis 1981; 3:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/9\">",
"      Yeager H Jr, Raleigh JW. Pulmonary disease due to Mycobacterium intracellulare. Am Rev Respir Dis 1973; 108:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/10\">",
"      Research Committee of the British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001; 56:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/11\">",
"      Wallace RJ Jr, Brown BA, Griffith DE, et al. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med 1994; 149:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/12\">",
"      Griffith DE, Brown BA, Girard WM, et al. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin Infect Dis 1996; 23:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/13\">",
"      Dautzenberg B, Saint Marc T, Meyohas MC, et al. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch Intern Med 1993; 153:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/14\">",
"      Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex for adults and adolescents infected with human immunodeficiency virus. U.S. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. MMWR Recomm Rep 1993; 42:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/15\">",
"      Kunin CM. Antimicrobial activity of rifabutin. Clin Infect Dis 1996; 22 Suppl 1:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/16\">",
"      Meier A, Kirschner P, Springer B, et al. Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob Agents Chemother 1994; 38:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/17\">",
"      Heifets L, Mor N, Vanderkolk J. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother 1993; 37:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/18\">",
"      Wallace RJ Jr, Brown BA, Griffith DE, et al. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med 1996; 153:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/19\">",
"      Dautzenberg B, Piperno D, Diot P, et al. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France. Chest 1995; 107:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/20\">",
"      Griffith DE, Brown BA, Girard WM, et al. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 2001; 32:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/21\">",
"      Griffith DE, Brown BA, Cegielski P, et al. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis 2000; 30:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/22\">",
"      Wallace RJ Jr, Brown BA, Griffith DE. Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis 1993; 16:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/23\">",
"      Lam PK, Griffith DE, Aksamit TR, et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006; 173:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/24\">",
"      Griffith DE, Brown-Elliott BA, Langsjoen B, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006; 174:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/25\">",
"      van Ingen J, Egelund EF, Levin A, et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med 2012; 186:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/26\">",
"      Griffith DE, Winthrop KL. Mycobacterium avium complex lung disease therapy. Am J Respir Crit Care Med 2012; 186:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/27\">",
"      Koh WJ, Jeong BH, Jeon K, et al. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012; 186:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/28\">",
"      Corpe RF. Surgical management of pulmonary disease due to Mycobacterium avium-intracellulare. Rev Infect Dis 1981; 3:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/29\">",
"      Shiraishi Y, Nakajima Y, Takasuna K, et al. Surgery for Mycobacterium avium complex lung disease in the clarithromycin era. Eur J Cardiothorac Surg 2002; 21:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/30\">",
"      Nelson KG, Griffith DE, Brown BA, Wallace RJ Jr. Results of operation in Mycobacterium avium-intracellulare lung disease. Ann Thorac Surg 1998; 66:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/31\">",
"      Shiraishi Y, Fukushima K, Komatsu H, Kurashima A. Early pulmonary resection for localized Mycobacterium avium complex disease. Ann Thorac Surg 1998; 66:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/32\">",
"      Shiraishi Y, Nakajima Y, Katsuragi N, et al. Pneumonectomy for nontuberculous mycobacterial infections. Ann Thorac Surg 2004; 78:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/33\">",
"      Sherwood JT, Mitchell JD, Pomerantz M. Completion pneumonectomy for chronic mycobacterial disease. J Thorac Cardiovasc Surg 2005; 129:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/34\">",
"      Watanabe M, Hasegawa N, Ishizaka A, et al. Early pulmonary resection for Mycobacterium avium complex lung disease treated with macrolides and quinolones. Ann Thorac Surg 2006; 81:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/35\">",
"      Sauret J, Hern&aacute;ndez-Flix S, Castro E, et al. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy. Tuber Lung Dis 1995; 76:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/36\">",
"      Brown BA, Wallace RJ Jr, Onyi GO, et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992; 36:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/37\">",
"      Dautzenberg B, Truffot C, Legris S, et al. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. Am Rev Respir Dis 1991; 144:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/38\">",
"      Green PA, von Reyn CF, Smith RP Jr. Mycobacterium avium complex parotid lymphadenitis: successful therapy with clarithromycin and ethambutol. Pediatr Infect Dis J 1993; 12:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/39\">",
"      Griffith DE, Brown-Elliott BA, Wallace RJ Jr. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis 2003; 37:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/40\">",
"      Guna R, Mu&ntilde;oz C, Dom&iacute;nguez V, et al. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. J Antimicrob Chemother 2005; 55:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/41\">",
"      Rodriguez D&iacute;az JC, L&oacute;pez M, Ruiz M, Royo G. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. Int J Antimicrob Agents 2003; 21:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/42\">",
"      Alcaide F, Calatayud L, Sant&iacute;n M, Mart&iacute;n R. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother 2004; 48:4562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/43\">",
"      Wallace RJ Jr, Dunbar D, Brown BA, et al. Rifampin-resistant Mycobacterium kansasii. Clin Infect Dis 1994; 18:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/44\">",
"      Brown-Elliott BA, Crist CJ, Mann LB, et al. In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria. Antimicrob Agents Chemother 2003; 47:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/45\">",
"      Shitrit D, Baum GL, Priess R, et al. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. Chest 2006; 129:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/46\">",
"      Majoor CJ, Schreurs AJ, Weers-Pothoff G. Mycobacterium xenopi infection in an immunosuppressed patient with Crohn's disease. Thorax 2004; 59:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/47\">",
"      Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment. Eur Respir J 2003; 21:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/48\">",
"      Jenkins PA, Campbell IA, Banks J, et al. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 2008; 63:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/49\">",
"      Andr&eacute;jak C, Lescure FX, Pukenyte E, et al. Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax 2009; 64:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/50\">",
"      van Ingen J, Boeree MJ, de Lange WC, et al. Mycobacterium xenopi clinical relevance and determinants, the Netherlands. Emerg Infect Dis 2008; 14:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/51\">",
"      van Ingen J, Boeree MJ, de Lange WC, et al. Clinical relevance of Mycobacterium szulgai in The Netherlands. Clin Infect Dis 2008; 46:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2441/abstract/52\">",
"      van Ingen J, Boeree MJ, Dekhuijzen PN, van Soolingen D. Clinical relevance of Mycobacterium simiae in pulmonary samples. Eur Respir J 2008; 31:106.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5341 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.25.216.6-8F673A88A0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_24_2441=[""].join("\n");
var outline_f2_24_2441=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MYCOBACTERIUM AVIUM COMPLEX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Recommended regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Macrolide-resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86941664\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86941713\">",
"      - Monitoring for clinical response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86941720\">",
"      - Therapeutic drug monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MYCOBACTERIUM KANSASII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Rifampin resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Treatment duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OTHER NONTUBERCULOUS MYCOBACTERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Mycobacterium malmoense",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mycobacterium xenopi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Mycobacterium szulgai",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Mycobacterium simiae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Rapidly growing mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5341\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5341|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/48/11020\" title=\"table 1\">",
"      Criteria for NTM diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11045?source=related_link\">",
"      Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=related_link\">",
"      Microbiology of nontuberculous mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24759?source=related_link\">",
"      Overview of nontuberculous mycobacterial infections in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15400?source=related_link\">",
"      Preoperative evaluation for lung resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5530?source=related_link\">",
"      Rapidly growing mycobacterial infections in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_24_2442="Clinical features, diagnosis, and treatment of neonatal encephalopathy";
var content_f2_24_2442=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features, diagnosis, and treatment of neonatal encephalopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/24/2442/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/24/2442/contributors\">",
"     Yvonne Wu, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/24/2442/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/24/2442/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/24/2442/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/24/2442/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/24/2442/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/24/2442/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal encephalopathy is a heterogeneous syndrome characterized by symptoms of central nervous system dysfunction in newborns born at term or late preterm (&ge;36 weeks gestation). An infant with neonatal encephalopathy may exhibit abnormal level of consciousness, seizures, tone and reflex abnormalities, apnea, and feeding difficulties [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Researchers have yet to adopt a consensus definition of neonatal encephalopathy. Some investigators require stringent criteria, such as two or more symptoms of encephalopathy lasting over 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/2\">",
"     2",
"    </a>",
"    ], while others require no more than a low 5 minute Apgar score [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neonatal encephalopathy can result from a wide variety of conditions and often remains unexplained. Birth asphyxia and hypoxic-ischemic (anoxic) encephalopathy are responsible for some, but not all cases of neonatal encephalopathy. Given that the underlying nature of brain injury causing neurologic impairment in a newborn is often poorly understood, \"neonatal encephalopathy\" has emerged as the preferred terminology to describe central nervous system dysfunction in the newborn period, as it does not imply a specific underlying pathophysiology [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of neonatal encephalopathy depends on how the syndrome is defined, but varies between two to nine per 1000 term births [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. As the term neonatal encephalopathy has become increasingly favored, it has been shown in one US population that the diagnosis of \"birth asphyxia\" has declined over the past decade [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This section will review the current state of knowledge regarding the diagnosis, prognosis and treatment of neonatal encephalopathy. The pathogenesis of neonatal encephalopathy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30953?source=see_link\">",
"     \"Etiology and pathogenesis of neonatal encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND NEONATAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neonate who is encephalopathic may have an abnormal state of consciousness (eg, hyperalert, irritable, lethargic, obtunded), respiratory or feeding difficulties, poor tone or seizure activity. In the delivery room, the infant will often exhibit low Apgar scores and a weak or absent cry.",
"   </p>",
"   <p>",
"    The diagnosis of neonatal encephalopathy necessitates a search for potential etiologies. A gross and histologic examination of the placenta and cord may provide evidence of a possible cause, such as a placental vascular lesion or infection, or a cord thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/8\">",
"     8",
"    </a>",
"    ]. A thorough maternal and family history is recommended, including a history of thromboembolic disorders, prior pregnancy loss, maternal infection, and maternal drug use. Samples are drawn to determine arterial cord pH and base deficit. The presence of oliguria, cardiomyopathy, or abnormal liver function tests may suggest a global hypoxic-ischemic event. Metabolic derangements, unusual odors, dysmorphic features, and congenital anomalies may suggest the presence of an inborn error of metabolism or genetic disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroimaging has become increasingly important in the evaluation of neonatal encephalopathy, and may provide information regarding the type and timing of brain injury [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. For instance, several patterns of brain injury seen in term and late preterm infants are considered to be typical of hypoxic-ischemic brain injury. These include parasagittal injury in the arterial watershed distribution and injury to the deep gray nuclei (lateral thalami, posterior putamina) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/4,11-14\">",
"     4,11-14",
"    </a>",
"    ] which correspond to brain damage seen in animal models of acute total asphyxia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, a head imaging study may reveal a developmental brain malformation, focal arterial infarction, or intraparenchymal hemorrhage, indicating a different underlying pathogenesis. In one study, 30 percent of infants with neonatal encephalopathy demonstrated a completely normal head MRI during the newborn period, indicating a good prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The findings on head CT and MRI may also provide insight into the time during which the injury occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In a study of 351 term infants with neonatal encephalopathy, MRI scans performed in the first one to two weeks of birth suggested that the majority of infants sustained brain injury that occurred acutely in the perinatal period [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30953?source=see_link\">",
"     \"Etiology and pathogenesis of neonatal encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Various modalities have been used to evaluate infant brains with neonatal encephalopathy, including cranial sonography (CS), computed tomography (CT) and magnetic resonance imaging (MRI) with MR spectroscopy. Head MR imaging techniques yield the most useful information, though the resources necessary for transporting, monitoring, and supporting sick babies during this procedure are not always readily available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=see_link\">",
"     \"Approach to neuroimaging in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Cranial sonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cranial sonography has the advantage of being noninvasive and available at the infant's bedside. Cranial sonography has a high sensitivity and specificity (91 and 81 percent, respectively) for locating hemorrhages and defining ventricular size [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/18\">",
"     18",
"    </a>",
"    ]. It may also detect severe parasagittal white matter damage and obvious cystic lesions, but it does not adequately image the outer limits of the cerebral cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/19\">",
"     19",
"    </a>",
"    ], nor is cranial sonography a sensitive tool for identifying milder white matter abnormalities that can be appreciated on head MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/20\">",
"     20",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Cranial sonography can be used to detect severe cerebral edema. Findings include increased echogenicity that causes sulci and fissures to be obscured, blurring of other anatomical landmarks, decreased arterial pulsations, and compression of the ventricles [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. After a few days, areas of echodensity that correspond to regions of necrosis may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. However, determining if early echodensities are areas of infarction or hemorrhage in the term brain is not always possible [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8678972\">",
"    <span class=\"h3\">",
"     Head CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head CT is the most useful imaging modality for diagnosing intracranial hemorrhage and brain calcifications. Cerebral edema, denoted by decreased attenuation of white matter and difficulty distinguishing gray from white matter, may also be appreciated on head CT, along with cerebral atrophy, ventricular size, and severe white matter lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. However, the white matter in a term newborn brain contains high water content, and therefore milder degrees of edema and white matter injury can be difficult to appreciate on head CT. Abnormalities of the posterior fossa are also often obscured by bony artifact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Head MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have described the increasing role that MR imaging plays in the diagnosis of neonatal encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/9,10,13,28-30\">",
"     9,10,13,28-30",
"    </a>",
"    ]. A head MRI is the most sensitive imaging tool for detecting periventricular white matter injury, deep gray matter lesions, arterial infarction, hemorrhage, developmental brain malformations, and other underlying causes of neonatal encephalopathy. Deep gray matter lesions involving the bilateral basal ganglia and thalami are particularly common findings on brain MRI in encephalopathic term infants with a recognized preceding sentinel hypoxic-ischemic event such as placental abruption, uterine rupture, and cord prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Academy of Neurology (AAN) practice parameter suggests that a head CT be performed in cases of neonatal encephalopathy to rule out hemorrhagic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/9\">",
"     9",
"    </a>",
"    ]. However, a head MRI is recommended in order to establish a pattern of injury and to predict neurologic outcome if the findings on head CT are inconclusive. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to conventional MRI, MR spectroscopy and diffusion-weighted imaging (DWI) techniques can provide useful information regarding timing and outcome of brain injury resulting in neonatal encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/10,28,30,31\">",
"     10,28,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Electroencephalography",
"    </span>",
"    &nbsp;&mdash;&nbsp;An electroencephalogram (EEG) can help to distinguish neonatal seizures from other phenomena, and can also identify subclinical seizures. Although the EEG is not helpful for determining the cause of neonatal encephalopathy, it can provide evidence for the presence and severity of encephalopathy, as well as provide prognostic information. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Amplitude integrated EEG, a continuous single channel recording of background cerebral electrical activity, is easy to use and interpret at the bedside, and has been used to distinguish mild from severe neonatal encephalopathy in large clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diagnosis of neonatal asphyxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxic-ischemic encephalopathy (HIE, also called birth asphyxia) is a subset of neonatal encephalopathy. It is unclear how often birth asphyxia is responsible for neonatal encephalopathy, as there is no gold standard for determining the presence of hypoxic-ischemic encephalopathy. It is well known that the various clinical signs of birth asphyxia, including Apgar scores, low cord pH, neonatal seizures and encephalopathy, are nonspecific and may occur in the absence of global hypoxic-ischemic brain injury or long-term neurologic sequelae. In a population-based study of neonatal encephalopathy, only 4 percent of cases had evidence of intrapartum hypoxia in the absence of antepartum risk factors, and 25 percent had both antepartum risk factors and intrapartum signs and symptoms of hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30953?source=see_link&amp;anchor=H5#H5\">",
"     \"Etiology and pathogenesis of neonatal encephalopathy\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     ACOG criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although its true incidence is unclear, birth asphyxia is a well-known and important contributor to neonatal encephalopathy. In order to identify cases of perinatal brain injury due to birth asphyxia, the American College of Obstetricians and Gynecologists (ACOG) developed a consensus statement regarding the criteria needed to define an intrapartum hypoxic-ischemic insult that is severe enough to cause a neonatal encephalopathy that subsequently leads to cerebral palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/17\">",
"     17",
"    </a>",
"    ]. The following four criteria are required:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Profound metabolic acidosis (pH less than 7.00 and base deficit &ge;12",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      on an umbilical cord arterial blood sample",
"     </li>",
"     <li>",
"      Early onset of severe or moderate neonatal encephalopathy in infants born at 34 or more weeks of gestation",
"     </li>",
"     <li>",
"      Cerebral palsy of the spastic quadriplegic or dyskinetic type",
"     </li>",
"     <li>",
"      Exclusion of other identifiable etiologies such as trauma, coagulation disorders, infectious conditions, or genetic disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional criteria suggesting an intrapartum timing, but nonspecific to asphyxia, include a sentinel hypoxic event during labor, severe electronic fetal monitoring abnormalities, Apgar score of 0 to 3 beyond five minutes, onset of multisystem involvement within 72 hours of birth, and early imaging study showing evidence of acute nonfocal cerebral abnormality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Limitations of ACOG criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been suggested that these guidelines are somewhat arbitrary (eg, the cut-off for cord pH), and that it may be too simplistic to think that a single set of nonspecific signs and symptoms can provide robust criteria for distinguishing underlying causal pathways. As an example, the presence of an infectious condition such as chorioamnionitis would preclude an intrapartum asphyxial event as being responsible for neonatal encephalopathy and subsequent cerebral palsy, according to the ACOG guidelines. Yet a maternal infection may play a role in causing hypoxic-ischemic brain injury in the fetus, and there is no reason to think that both cannot occur in the same infant [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/33\">",
"     33",
"    </a>",
"    ]. Of note, the etiology of cerebral palsy is multifactorial. Most cases are thought to result from prenatal factors such as prematurity, intrauterine growth restriction, intrauterine infection, antepartum hemorrhage, severe placental pathology, and multiple pregnancies. Perinatal hypoxia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ischemia likely account for only a small minority of cases of cerebral palsy. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=see_link\">",
"     \"Epidemiology and etiology of cerebral palsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Until a more specific diagnostic test for hypoxic-ischemic brain injury is widely available, the attribution of neonatal encephalopathy and cerebral palsy to birth asphyxia rests on clinical criteria as listed above. It remains to be established whether neuroimaging or other testing can one day be used as a gold standard for determining when birth asphyxia and hypoxic-ischemic brain injury is responsible for neonatal encephalopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood and extent of brain damage is related to the degree of neonatal encephalopathy. Most infants with mild to moderate degrees of encephalopathy develop normally, while infants with severe encephalopathy are more likely to develop long-term neurologic morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/7,34-38\">",
"     7,34-38",
"    </a>",
"    ]. Severe MRI abnormalities are usually associated with marked EEG abnormalities and poor outcome.",
"   </p>",
"   <p>",
"    Permanent neurologic sequelae can be mild, such as learning difficulties or attention deficit disorder, or may be severe and disabling, including cerebral palsy, epilepsy, visual impairment and severe cognitive and developmental disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although definitions vary, the degree of neonatal encephalopathy has been categorized by some as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mild: hyperalert, hyperexcitable, normal muscle tone, no seizures",
"     </li>",
"     <li>",
"      Moderate: hypotonia, decreased movements, and often seizures",
"     </li>",
"     <li>",
"      Severe: stuporous, flaccid, and absent primitive reflexes, usually with seizures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Term infants with mild neonatal encephalopathy in the neonatal period have a high probability of being normal at follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/7,34\">",
"     7,34",
"    </a>",
"    ]. Infants with moderate encephalopathy have a 20 to 35 percent risk of later sequelae from the insult, although those whose neurologic examinations are completely normal within one week have a good likelihood of normal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/36\">",
"     36",
"    </a>",
"    ]. Infants with severe encephalopathy have a 75 percent risk of dying in the neonatal period, and among survivors, an almost universal risk of sequelae exists [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/34,36,40,41\">",
"     34,36,40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Scoring systems have been devised to help predict an infant's subsequent risk for developing cerebral palsy or systemic morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/39,42,43\">",
"     39,42,43",
"    </a>",
"    ]. One of the largest studies retrospectively evaluated 365 infants with HIE and found that three clinical parameters &mdash; administration of chest compression for &gt;1 minute, onset of regular respirations &gt;30 minutes after birth, and base deficit value of &gt;16",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    on any blood gas analysis within the first four hours from birth &mdash; were predictors of severe adverse outcome (death or severe disability) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/43\">",
"     43",
"    </a>",
"    ]. Severe outcome rates with none, one, two, or all three predictors were 46, 64, 76, and 93 percent, respectively.",
"   </p>",
"   <p>",
"    Seizures may be a predictor of poor outcome, but data are inconsistent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a longitudinal report of 129 children ages 12 months to 16.5 years (median 6 years) who survived neonatal encephalopathy, epilepsy developed in 13 (10 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/44\">",
"       44",
"      </a>",
"      ]. Risk factors for the development of epilepsy were the occurrence of neonatal seizures, particularly status epilepticus, and neonatal brain injury on MRI. All children with epilepsy had unfavorable neurodevelopmental outcomes.",
"     </li>",
"     <li>",
"      Another report analyzed data from subjects enrolled in a therapeutic hypothermia trial and compared 127 infants who had clinical seizures during the trial with 81 infants who had no seizures [",
"      <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/45\">",
"       45",
"      </a>",
"      ]. After adjusting for study treatment and severity of encephalopathy, seizures were",
"      <strong>",
"       not",
"      </strong>",
"      associated with poor outcomes at 18 months of life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A separate issue is that treatment with hypothermia (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Therapeutic hypothermia'",
"    </a>",
"    below) may diminish the value of clinical findings and electroencephalography (see",
"    <a class=\"local\" href=\"#H14\">",
"     'EEG predictors'",
"    </a>",
"    below) for predicting outcome among survivors of neonatal encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. However, in a post-hoc analysis of the NICHD trial, the clinical findings after 72 hours of cooling were good predictors of outcome; persistence of severe hypoxic-ischemic encephalopathy at 72 hours and an abnormal neurologic examination at the time of hospital discharge were associated with an increased risk of death or disability at 18 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no established biomarkers for determining the extent of neonatal brain injury or predicting outcome in infants with neonatal encephalopathy. In a systematic review published in 2009, serum interleukin-1B, serum interleukin-6, cerebrospinal fluid neuron-specific enolase (NSE), and cerebrospinal fluid interleukin-1B (all measured before age 96 hours) were putative predictors of abnormal outcomes at age &ge;12 months in survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/50\">",
"     50",
"    </a>",
"    ]. However, all included studies had small patient numbers and significant heterogeneity. In a later uncontrolled report of 75 term newborns with neonatal encephalopathy who were treated with hypothermia, the group with unfavorable outcomes at 14 days of life had significantly elevated levels of serum S100B and NSE in the first 72 hours of cooling compared with the favorable outcomes group [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/51\">",
"     51",
"    </a>",
"    ]. Given the shortcomings of these data, further studies are needed to determine if any of these biomarkers is useful for the early assessment of infants with neonatal encephalopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neuroimaging predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroimaging findings can be helpful for predicting long-term outcome following neonatal encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/10,52-54\">",
"     10,52-54",
"    </a>",
"    ]. Abnormal signal in the posterior limb of the internal capsule appreciated on a head MRI obtained in the first two weeks of life has been shown to predict adverse neurologic outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/52,55\">",
"     52,55",
"    </a>",
"    ]. In term infants with neonatal encephalopathy, lesions affecting bilateral basal ganglia and thalami that are detected by MRI in the first weeks of life have been associated with poor neurologic outcomes and death [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/13,14,52\">",
"     13,14,52",
"    </a>",
"    ]. In one study, brainstem lesions on MRI were associated with an increased risk of death [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapeutic hypothermia (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Therapeutic hypothermia'",
"    </a>",
"    below) appears to decrease the degree of brain injury observed on MRI and magnetic resonance spectroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/56-60\">",
"     56-60",
"    </a>",
"    ]. Nevertheless, the available evidence suggests that treatment with hypothermia does not affect the value of MRI for predicting outcome after neonatal encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/57,59,60\">",
"     57,59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diffusion-weighted MRI can detect the presence of acute brain injury in a neonate, and thus distinguish which infants with neonatal encephalopathy have suffered a significant brain injury that is associated with adverse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/12,53,54,61\">",
"     12,53,54,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Magnetic resonance spectroscopy can detect increased lactate and decreased N-acetyl aspartate indicating derangements of the metabolic state of specific regions of the brain, which has also been shown to portend a worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/28,62-64\">",
"     28,62-64",
"    </a>",
"    ]. In cases of perinatal arterial stroke, the presence of internal capsule and basal ganglia injury has been correlated with increased risk of hemiparesis and long-term neurologic sequelae, especially when seen in conjunction with cortical injury [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/65-67\">",
"     65-67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     EEG predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings on electroencephalogram (EEG) and amplitude-integrated electroencephalogram (aEEG) can also be used to help prognosticate. An EEG that shows severe background abnormalities including burst suppression, isoelectricity or extremely low voltage portends a high likelihood of death or significant long-term neurologic sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Since severe MRI abnormalities are usually associated with marked EEG abnormalities and poor outcome, the EEG may be especially helpful as a prognostic tool in the setting of moderate MRI abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although severe abnormalities seen on EEG within the first 24 hours of life can be a useful predictor of outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/71,72\">",
"     71,72",
"    </a>",
"    ], a follow-up EEG showing recovery of normal electrical activity may be associated with a much improved outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/72,73\">",
"     72,73",
"    </a>",
"    ], indicating the importance of serial EEG examinations.",
"   </p>",
"   <p>",
"    A 2012 systematic review identified 29 observational studies that evaluated 13 prognostic tests applied to term infants with hypoxic-ischemic encephalopathy who had at least 18 months of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/54\">",
"     54",
"    </a>",
"    ]. When obtained within the first week after birth, the best performing prognostic tests were aEEG (pooled sensitivity and specificity, 0.93 and 0.90) and routine EEG (pooled sensitivity and specificity, 0.92 and 0.83). However, the confidence intervals for these data were wide because of small patient numbers in the included studies.",
"   </p>",
"   <p>",
"    Limited evidence suggests that aEEG is altered in the setting of hypothermia treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/48\">",
"     48",
"    </a>",
"    ]. In one study that compared 43 infants treated with hypothermia and 31 treated with normothermia, early (&lt;6 hours) aEEG background abnormalities in infants treated with hypothermia were poorly correlated with outcome. In contrast, recovery time to normal background, and time to onset of sleep-wake cycling were more predictive of outcome in cooled infants than in non-cooled infants. In addition, having a normal aEEG pattern within six hours of delivery predicted a normal outcome in both cooled and non-cooled infants. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of moderate and severe neonatal encephalopathy should take place in a neonatal intensive care unit. Major goals include the maintenance of physiologic homeostasis and treatment of the outward manifestations of brain injury [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Central aspects of supportive care include the following (see",
"    <a class=\"local\" href=\"#H8678465\">",
"     'Supportive management'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maintenance of adequate ventilation (avoidance of hypoxemia or hyperoxia)",
"     </li>",
"     <li>",
"      Maintenance of sufficient brain and organ perfusion (avoidance of systemic hypotension or hypertension; avoidance of hyperviscosity)",
"     </li>",
"     <li>",
"      Maintenance of normal metabolic status (eg, normoglycemia, nutritional status, pH)",
"     </li>",
"     <li>",
"      Control of seizures",
"     </li>",
"     <li>",
"      Control of brain edema (avoidance of fluid overload)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Therapeutic hypothermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with hypothermia improves survival and outcome at 18 months after neonatal asphyxia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neonatal encephalopathy. This conclusion is supported by a 2012 meta-analysis of seven randomized controlled trials of therapeutic hypothermia involving 1214 newborns with moderate to severe neonatal encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/76\">",
"     76",
"    </a>",
"    ]. In all the included trials, hypothermia was started within six hours after birth. Four of the trials (NICHD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/77\">",
"     77",
"    </a>",
"    ], TOBY [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/78\">",
"     78",
"    </a>",
"    ], neo.nEURO.network [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/79\">",
"     79",
"    </a>",
"    ], and ICE [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/80\">",
"     80",
"    </a>",
"    ]) used whole body cooling while three (CoolCap [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/32\">",
"     32",
"    </a>",
"    ] and two others [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]) employed selective head cooling. The duration of hypothermia was 72 hours, with the exception of one small trial that stopped cooling between 48 and 72 hours for newborns who recovered neurologically [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/82\">",
"     82",
"    </a>",
"    ]. The overall methodologic quality of the included trials was high. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At age 18 months, therapeutic hypothermia compared with usual care led to a significant reduction in the composite primary outcome of death or major neurodevelopmental disability (48 versus 63 percent, risk ratio [RR] 0.76, 95% CI 0.69-0.84) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In subgroup analysis, the benefit of therapeutic hypothermia for reducing death or major neurodevelopmental disability was statistically significant for newborns with both moderate and severe hypoxic-ischemic encephalopathy (RR 0.67, 95% CI 0.56-0.81 and RR 0.83, 95% CI 0.74-0.92, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/76\">",
"       76",
"      </a>",
"      ]. To save one newborn from death or major disability, the number needed to treat (NNT) for those with moderate hypoxic-ischemic encephalopathy was 6, while the NNT for those with severe hypoxic-ischemic encephalopathy was 7.",
"     </li>",
"     <li>",
"      The reduced risk of death or major neurodevelopmental disability was seen with both total body cooling and selective head cooling (RR 0.75, 95% CI 0.66-0.85 and RR 0.77, 95% CI 0.65-0.93, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Therapeutic hypothermia increased survival with a normal neurologic outcome at 18 months (40 versus 24 percent, RR 1.63, 95% CI 1.36-1.95) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data regarding the long-term safety and efficacy of therapeutic hypothermia are limited. The NICHD trial assessed outcomes at ages six to seven years for 190 of the original 209 trial participants [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/83\">",
"     83",
"    </a>",
"    ]. The proportion who died or had an IQ score &lt;70 was lower for children assigned to the hypothermia group compared with the control group (47 versus 62 percent) but the difference between the groups just missed statistical significance (RR 0.78, 95% CI 0.61-1.01). While these results suggest that the benefit of therapeutic hypothermia extends later into childhood, more data are needed to confirm long-term benefit.",
"   </p>",
"   <p>",
"    Of note, secondary analyses of control infants in the NICHD and CoolCap trials found a significant association between elevated temperature and adverse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. These observational data do not establish causality, and additional studies are needed to determine whether reducing temperatures to normothermic levels will improve neurologic outcomes in infants who do not receive therapeutic hypothermia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothermia is the only effective neuroprotective therapy currently available for treatment of neonatal encephalopathy. It is easy to administer and appears to be safe. There is a consensus among experts that therapeutic hypothermia should be more widely available, based upon the benefit and safety of hypothermia, and the lack of other effective treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/46,86,87\">",
"     46,86,87",
"    </a>",
"    ]. Thus, an increasing number of neonatal intensive care units in the US, Europe, Australia, and Japan are providing therapeutic hypothermia, and national guidelines support the use of therapeutic hypothermia for infants who meet the criteria used in the published trials [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/88-91\">",
"     88-91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although direct comparisons are lacking, selective head cooling and whole body cooling appear to have similar safety and effectiveness. Whole body cooling is preferred in most centers in the United States due to ease of administration. Whole body cooling also provides easier access to the scalp for EEG monitoring.",
"   </p>",
"   <p>",
"    Despite the promising clinical trial results, therapeutic hypothermia has limited efficacy, as illustrated by the 2012 meta-analysis of the major trials, in which nearly one-half of all infants who were treated with hypothermia either died or had major neurodevelopmental disability at 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/76\">",
"     76",
"    </a>",
"    ]. In addition, data regarding long-term safety and efficacy of therapeutic hypothermia beyond 18 to 24 months are limited, and the utility of this therapy has not been studied for premature infants or infants with severe intrauterine growth restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/92-94\">",
"     92-94",
"    </a>",
"    ]. Therefore, additional neuroprotective therapies and studies are urgently needed for neonatal encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the data from controlled trials and meta-analyses showing benefit for therapeutic hypothermia, our recommendations are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For term or late preterm infants with neonatal encephalopathy, we suggest the use of therapeutic head cooling or whole body cooling as early therapy (in the first six hours of life) in experienced centers. Implementation of therapeutic hypothermia should follow published protocols employed in one of the major published trials [",
"      <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/32,77-81\">",
"       32,77-81",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Therapeutic hypothermia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When therapeutic hypothermia is not used, we suggest close monitoring of core body temperature. Although it is unknown whether lowering body temperature to normothermic levels alters outcome in this setting, it is reasonable to avoid hyperthermia given currently available data. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Therapeutic hypothermia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8678465\">",
"    <span class=\"h2\">",
"     Supportive management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aside from treatment with hypothermia, suggested management of HIE includes the following recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluate with an electroencephalogram (EEG) to gather information regarding diagnosis, treatment and prognosis of neonatal encephalopathy. Serial EEGs may be helpful in further defining the prognosis. The amplitude integrated EEG may be helpful for predicting outcome and identifying seizure activity in infants with neonatal encephalopathy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'EEG predictors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obtain a head imaging study, preferably with MRI. Cranial sonography is not as sensitive as head MRI or CT. Specific findings on head MRI can be useful for establishing the pathogenesis and prognosis of neonatal encephalopathy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treat seizures with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/63/29689?source=see_link\">",
"       phenobarbital",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"       lorazepam",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/45/23258?source=see_link\">",
"       fosphenytoin",
"      </a>",
"      . The optimal therapeutic agent, as well as the duration of treatment, has not been adequately evaluated. This topic is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/0/13?source=see_link\">",
"       \"Treatment of neonatal seizures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Perform a lumbar puncture to assess for intracranial bleeding or infection, especially since meningitis can mimic the signs and symptoms of neonatal encephalopathy. Antibiotics are started until infection is ruled out, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      is initiated if herpes simplex virus is suspected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25625?source=see_link\">",
"       \"Lumbar puncture: Indications, contraindications, technique, and complications in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Use high frequency ventilation, nitric oxide, or extracorporeal membrane oxygenation therapies, as available, for infants with persistent fetal circulation syndrome to maintain oxygenation.",
"     </li>",
"     <li>",
"      Replace volume and use inotropic agents as required to maintain blood pressure and adequate cerebral perfusion. However, systemic hypertension and volume overload, which can worsen cerebral edema, should be avoided.",
"     </li>",
"     <li>",
"      Arterial blood gases and serum calcium, magnesium, glucose, and electrolytes should be assessed early in the course and as needed. Liver enzymes and serum creatinine are measured to determine injury to other end organs.",
"     </li>",
"     <li>",
"      Early treatment may be crucial to outcome if a metabolic disorder is suspected. Feeds should be stopped, acidosis and hypoglycemia corrected, and specific treatment such as vitamin supplementation or hemodialysis considered after consultation with a geneticist. Specific testing for ammonia, lactate and pyruvate, serum amino acids and urine organic acids are also required to rule out a metabolic cause of neonatal encephalopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Future prospects",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of potential neuroprotective treatments are being studied both to prevent the cascade of injurious effects after hypoxia-ischemia. As an example, erythropoietin has neuroprotective properties in animal models of hypoxic-ischemic brain injury and neonatal stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/95-98\">",
"     95-98",
"    </a>",
"    ]. A preliminary randomized trial of 167 neonates with HIE found that treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/51/17208?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    for two weeks, starting within 48 hours of birth, was associated with improved neurologic outcome at 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/99\">",
"     99",
"    </a>",
"    ]. Confirmation of benefit in larger trials is needed.",
"   </p>",
"   <p>",
"    Additional strategies that may be useful as adjuncts to hypothermia include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?2/24/2442/abstract/4,46,100,101\">",
"     4,46,100,101",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prevention of the build-up of superoxide radicals and other mediators of oxygen free radical-induced injury",
"     </li>",
"     <li>",
"      Reduction of glutamate receptor activation",
"     </li>",
"     <li>",
"      Prevention of intracellular calcium accumulation",
"     </li>",
"     <li>",
"      Administration of growth factors (monosialo-gangliosides, brain derived growth factor), nitric oxide synthase inhibitors, and blockers of apoptosis",
"     </li>",
"     <li>",
"      Reduction of secondary inflammatory reactions",
"     </li>",
"     <li>",
"      Tissue repair and regeneration",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8677534\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonatal encephalopathy is a heterogeneous syndrome characterized by symptoms of central nervous system dysfunction in newborns born at term or late preterm (&ge;36 weeks gestation). Neonatal encephalopathy can result from a wide variety of conditions and often remains unexplained. Birth asphyxia and hypoxic-ischemic (anoxic) encephalopathy are responsible for some, but not all cases of neonatal encephalopathy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The neonate who is encephalopathic may have an abnormal state of consciousness (eg, hyperalert, irritable, lethargic, obtunded), respiratory or feeding difficulties, poor tone, or seizure activity. Neuroimaging is important in the evaluation of neonatal encephalopathy, and may provide information regarding the type and timing of brain injury. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations and neonatal assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is unclear how often birth asphyxia is responsible for neonatal encephalopathy, as there is no gold standard for determining the presence of hypoxic-ischemic encephalopathy. The various clinical signs of birth asphyxia, including Apgar scores, low cord pH, neonatal seizures and encephalopathy, are nonspecific. To define an intrapartum hypoxic-ischemic insult that is severe enough to cause a neonatal encephalopathy that subsequently leads to cerebral palsy, the following four consensus criteria have been proposed (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis of neonatal asphyxia'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Profound metabolic acidosis (pH less than 7.00 and base deficit &ge;12",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      on an umbilical cord arterial blood sample",
"     </li>",
"     <li>",
"      Early onset of severe or moderate neonatal encephalopathy in infants born at 34 or more weeks of gestation",
"     </li>",
"     <li>",
"      Cerebral palsy of the spastic quadriplegic or dyskinetic type",
"     </li>",
"     <li>",
"      Exclusion of other identifiable etiologies such as trauma, coagulation disorders, infectious conditions, or genetic disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most infants with mild to moderate degrees of encephalopathy develop normally, while infants with severe encephalopathy are more likely to develop long-term neurologic morbidity. Severe MRI abnormalities are usually associated with marked EEG abnormalities and poor outcome. Permanent neurologic sequelae can be mild, such as learning difficulties or attention deficit disorder, or may be severe and disabling, including cerebral palsy, epilepsy, visual impairment, and severe cognitive and developmental disorders. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of moderate and severe neonatal encephalopathy should take place in a neonatal intensive care unit. Central aspects of supportive care include the following (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8678465\">",
"       'Supportive management'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Maintenance of adequate ventilation (avoidance of hypoxemia or hyperoxia)",
"     </li>",
"     <li>",
"      Maintenance of sufficient brain and organ perfusion (avoidance of systemic hypotension or hypertension; avoidance of hyperviscosity)",
"     </li>",
"     <li>",
"      Maintenance of normal metabolic status (eg, normoglycemia, nutritional status, pH)",
"     </li>",
"     <li>",
"      Control of seizures",
"     </li>",
"     <li>",
"      Control of brain edema (avoidance of fluid overload)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For term or late preterm infants with neonatal encephalopathy, we suggest the use of therapeutic head cooling or whole body cooling as early therapy (in the first six hours of life) in experienced centers (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). When therapeutic hypothermia is not used, we suggest close monitoring of core body temperature and measures to avoid hyperthermia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Therapeutic hypothermia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/1\">",
"      Nelson KB, Leviton A. How much of neonatal encephalopathy is due to birth asphyxia? Am J Dis Child 1991; 145:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/2\">",
"      Badawi N, Kurinczuk JJ, Keogh JM, et al. Antepartum risk factors for newborn encephalopathy: the Western Australian case-control study. BMJ 1998; 317:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/3\">",
"      Bartha AI, Foster-Barber A, Miller SP, et al. Neonatal encephalopathy: association of cytokines with MR spectroscopy and outcome. Pediatr Res 2004; 56:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/4\">",
"      Ferriero DM. Neonatal brain injury. N Engl J Med 2004; 351:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/5\">",
"      Wu YW, Backstrand KH, Zhao S, et al. Declining diagnosis of birth asphyxia in California: 1991-2000. Pediatrics 2004; 114:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/6\">",
"      Graham EM, Ruis KA, Hartman AL, et al. A systematic review of the role of intrapartum hypoxia-ischemia in the causation of neonatal encephalopathy. Am J Obstet Gynecol 2008; 199:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/7\">",
"      Thornberg E, Thiringer K, Odeback A, Milsom I. Birth asphyxia: incidence, clinical course and outcome in a Swedish population. Acta Paediatr 1995; 84:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/8\">",
"      Redline RW. Severe fetal placental vascular lesions in term infants with neurologic impairment. Am J Obstet Gynecol 2005; 192:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/9\">",
"      Ment LR, Bada HS, Barnes P, et al. Practice parameter: neuroimaging of the neonate: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2002; 58:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/10\">",
"      Chau V, Poskitt KJ, Miller SP. Advanced neuroimaging techniques for the term newborn with encephalopathy. Pediatr Neurol 2009; 40:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/11\">",
"      Barkovich AJ. MR and CT evaluation of profound neonatal and infantile asphyxia. AJNR Am J Neuroradiol 1992; 13:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/12\">",
"      Roland EH, Poskitt K, Rodriguez E, et al. Perinatal hypoxic-ischemic thalamic injury: clinical features and neuroimaging. Ann Neurol 1998; 44:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/13\">",
"      Miller SP, Ramaswamy V, Michelson D, et al. Patterns of brain injury in term neonatal encephalopathy. J Pediatr 2005; 146:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/14\">",
"      Okereafor A, Allsop J, Counsell SJ, et al. Patterns of brain injury in neonates exposed to perinatal sentinel events. Pediatrics 2008; 121:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/15\">",
"      Myers RE. Two patterns of perinatal brain damage and their conditions of occurrence. Am J Obstet Gynecol 1972; 112:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/16\">",
"      Cowan F, Rutherford M, Groenendaal F, et al. Origin and timing of brain lesions in term infants with neonatal encephalopathy. Lancet 2003; 361:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/17\">",
"      Hankins GD, Speer M. Defining the pathogenesis and pathophysiology of neonatal encephalopathy and cerebral palsy. Obstet Gynecol 2003; 102:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/18\">",
"      Hope PL, Gould SJ, Howard S, et al. Precision of ultrasound diagnosis of pathologically verified lesions in the brains of very preterm infants. Dev Med Child Neurol 1988; 30:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/19\">",
"      Shankaran S, Kottamasu SR, Kuhns L. Brain sonography, computed tomography, and single-photon emission computed tomography in term neonates with perinatal asphyxia. Clin Perinatol 1993; 20:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/20\">",
"      Miller SP, Cozzio CC, Goldstein RB, et al. Comparing the diagnosis of white matter injury in premature newborns with serial MR imaging and transfontanel ultrasonography findings. AJNR Am J Neuroradiol 2003; 24:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/21\">",
"      Martin DJ, Hill A, Fitz CR, et al. Hypoxic/ischaemic cerebral injury in the neonatal brain. A report of sonographic features with computed tomographic correlation. Pediatr Radiol 1983; 13:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/22\">",
"      Siegel MJ, Shackelford GD, Perlman JM, Fulling KH. Hypoxic-ischemic encephalopathy in term infants: diagnosis and prognosis evaluated by ultrasound. Radiology 1984; 152:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/23\">",
"      Hill A. Current concepts of hypoxic-ischemic cerebral injury in the term newborn. Pediatr Neurol 1991; 7:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/24\">",
"      Adsett DB, Fitz CR, Hill A. Hypoxic-ischaemic cerebral injury in the term newborn: correlation of CT findings with neurological outcome. Dev Med Child Neurol 1985; 27:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/25\">",
"      Fitzhardinge PM, Flodmark O, Fitz CR, Ashby S. The prognostic value of computed tomography as an adjunct to assessment of the term infant with postasphyxial encephalopathy. J Pediatr 1981; 99:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/26\">",
"      Graziani LJ, Pasto M, Stanley C, et al. Neonatal neurosonographic correlates of cerebral palsy in preterm infants. Pediatrics 1986; 78:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/27\">",
"      Lupton BA, Hill A, Roland EH, et al. Brain swelling in the asphyxiated term newborn: pathogenesis and outcome. Pediatrics 1988; 82:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/28\">",
"      Miller SP, Newton N, Ferriero DM, et al. Predictors of 30-month outcome after perinatal depression: role of proton MRS and socioeconomic factors. Pediatr Res 2002; 52:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/29\">",
"      Barnett A, Mercuri E, Rutherford M, et al. Neurological and perceptual-motor outcome at 5 - 6 years of age in children with neonatal encephalopathy: relationship with neonatal brain MRI. Neuropediatrics 2002; 33:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/30\">",
"      Heinz ER, Provenzale JM. Imaging findings in neonatal hypoxia: a practical review. AJR Am J Roentgenol 2009; 192:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/31\">",
"      Bydder GM, Rutherford MA. Diffusion-weighted imaging of the brain in neonates and infants. Magn Reson Imaging Clin N Am 2001; 9:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/32\">",
"      Gluckman PD, Wyatt JS, Azzopardi D, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet 2005; 365:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/33\">",
"      Wu YW, Escobar GJ, Grether JK, et al. Chorioamnionitis and cerebral palsy in term and near-term infants. JAMA 2003; 290:2677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/34\">",
"      Robertson C, Finer N. Term infants with hypoxic-ischemic encephalopathy: outcome at 3.5 years. Dev Med Child Neurol 1985; 27:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/35\">",
"      Robertson CM, Finer NN, Grace MG. School performance of survivors of neonatal encephalopathy associated with birth asphyxia at term. J Pediatr 1989; 114:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/36\">",
"      Finer NN, Robertson CM, Richards RT, et al. Hypoxic-ischemic encephalopathy in term neonates: perinatal factors and outcome. J Pediatr 1981; 98:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/37\">",
"      Levene ML, Kornberg J, Williams TH. The incidence and severity of post-asphyxial encephalopathy in full-term infants. Early Hum Dev 1985; 11:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/38\">",
"      van Handel M, Swaab H, de Vries LS, Jongmans MJ. Long-term cognitive and behavioral consequences of neonatal encephalopathy following perinatal asphyxia: a review. Eur J Pediatr 2007; 166:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/39\">",
"      Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study. Arch Neurol 1976; 33:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/40\">",
"      Shankaran S, Woldt E, Koepke T, et al. Acute neonatal morbidity and long-term central nervous system sequelae of perinatal asphyxia in term infants. Early Hum Dev 1991; 25:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/41\">",
"      Lacey JL, Henderson-Smart DJ. Assessment of preterm infants in the intensive-care unit to predict cerebral palsy and motor outcome at 6 years. Dev Med Child Neurol 1998; 40:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/42\">",
"      Thompson CM, Puterman AS, Linley LL, et al. The value of a scoring system for hypoxic ischaemic encephalopathy in predicting neurodevelopmental outcome. Acta Paediatr 1997; 86:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/43\">",
"      Shah PS, Beyene J, To T, et al. Postasphyxial hypoxic-ischemic encephalopathy in neonates: outcome prediction rule within 4 hours of birth. Arch Pediatr Adolesc Med 2006; 160:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/44\">",
"      Glass HC, Hong KJ, Rogers EE, et al. Risk factors for epilepsy in children with neonatal encephalopathy. Pediatr Res 2011; 70:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/45\">",
"      Kwon JM, Guillet R, Shankaran S, et al. Clinical seizures in neonatal hypoxic-ischemic encephalopathy have no independent impact on neurodevelopmental outcome: secondary analyses of data from the neonatal research network hypothermia trial. J Child Neurol 2011; 26:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/46\">",
"      Higgins RD, Raju T, Edwards AD, et al. Hypothermia and other treatment options for neonatal encephalopathy: an executive summary of the Eunice Kennedy Shriver NICHD workshop. J Pediatr 2011; 159:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/47\">",
"      Gunn AJ, Wyatt JS, Whitelaw A, et al. Therapeutic hypothermia changes the prognostic value of clinical evaluation of neonatal encephalopathy. J Pediatr 2008; 152:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/48\">",
"      Thoresen M, Hellstr&ouml;m-Westas L, Liu X, de Vries LS. Effect of hypothermia on amplitude-integrated electroencephalogram in infants with asphyxia. Pediatrics 2010; 126:e131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/49\">",
"      Shankaran S, Laptook AR, Tyson JE, et al. Evolution of encephalopathy during whole body hypothermia for neonatal hypoxic-ischemic encephalopathy. J Pediatr 2012; 160:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/50\">",
"      Ramaswamy V, Horton J, Vandermeer B, et al. Systematic review of biomarkers of brain injury in term neonatal encephalopathy. Pediatr Neurol 2009; 40:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/51\">",
"      Massaro AN, Chang T, Kadom N, et al. Biomarkers of brain injury in neonatal encephalopathy treated with hypothermia. J Pediatr 2012; 161:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/52\">",
"      Martinez-Biarge M, Diez-Sebastian J, Kapellou O, et al. Predicting motor outcome and death in term hypoxic-ischemic encephalopathy. Neurology 2011; 76:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/53\">",
"      Alderliesten T, de Vries LS, Benders MJ, et al. MR imaging and outcome of term neonates with perinatal asphyxia: value of diffusion-weighted MR imaging and &sup1;H MR spectroscopy. Radiology 2011; 261:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/54\">",
"      van Laerhoven H, de Haan TR, Offringa M, et al. Prognostic tests in term neonates with hypoxic-ischemic encephalopathy: a systematic review. Pediatrics 2013; 131:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/55\">",
"      Rutherford MA, Pennock JM, Counsell SJ, et al. Abnormal magnetic resonance signal in the internal capsule predicts poor neurodevelopmental outcome in infants with hypoxic-ischemic encephalopathy. Pediatrics 1998; 102:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/56\">",
"      Bonifacio SL, Glass HC, Vanderpluym J, et al. Perinatal events and early magnetic resonance imaging in therapeutic hypothermia. J Pediatr 2011; 158:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/57\">",
"      Rutherford M, Ramenghi LA, Edwards AD, et al. Assessment of brain tissue injury after moderate hypothermia in neonates with hypoxic-ischaemic encephalopathy: a nested substudy of a randomised controlled trial. Lancet Neurol 2010; 9:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/58\">",
"      Corbo ET, Bartnik-Olson BL, Machado S, et al. The effect of whole-body cooling on brain metabolism following perinatal hypoxic-ischemic injury. Pediatr Res 2012; 71:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/59\">",
"      Cheong JL, Coleman L, Hunt RW, et al. Prognostic utility of magnetic resonance imaging in neonatal hypoxic-ischemic encephalopathy: substudy of a randomized trial. Arch Pediatr Adolesc Med 2012; 166:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/60\">",
"      Shankaran S, Barnes PD, Hintz SR, et al. Brain injury following trial of hypothermia for neonatal hypoxic-ischaemic encephalopathy. Arch Dis Child 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/61\">",
"      Robertson RL, Ben-Sira L, Barnes PD, et al. MR line-scan diffusion-weighted imaging of term neonates with perinatal brain ischemia. AJNR Am J Neuroradiol 1999; 20:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/62\">",
"      Amess PN, Penrice J, Wylezinska M, et al. Early brain proton magnetic resonance spectroscopy and neonatal neurology related to neurodevelopmental outcome at 1 year in term infants after presumed hypoxic-ischaemic brain injury. Dev Med Child Neurol 1999; 41:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/63\">",
"      Hanrahan JD, Cox IJ, Azzopardi D, et al. Relation between proton magnetic resonance spectroscopy within 18 hours of birth asphyxia and neurodevelopment at 1 year of age. Dev Med Child Neurol 1999; 41:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/64\">",
"      Boichot C, Walker PM, Durand C, et al. Term neonate prognoses after perinatal asphyxia: contributions of MR imaging, MR spectroscopy, relaxation times, and apparent diffusion coefficients. Radiology 2006; 239:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/65\">",
"      Boardman JP, Ganesan V, Rutherford MA, et al. Magnetic resonance image correlates of hemiparesis after neonatal and childhood middle cerebral artery stroke. Pediatrics 2005; 115:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/66\">",
"      Mercuri E, Rutherford M, Cowan F, et al. Early prognostic indicators of outcome in infants with neonatal cerebral infarction: a clinical, electroencephalogram, and magnetic resonance imaging study. Pediatrics 1999; 103:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/67\">",
"      Lee J, Croen LA, Lindan C, et al. Predictors of outcome in perinatal arterial stroke: a population-based study. Ann Neurol 2005; 58:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/68\">",
"      Takeuchi T, Watanabe K. The EEG evolution and neurological prognosis of neonates with perinatal hypoxia [corrected]. Brain Dev 1989; 11:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/69\">",
"      Holmes GL, Lombroso CT. Prognostic value of background patterns in the neonatal EEG. J Clin Neurophysiol 1993; 10:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/70\">",
"      Biagioni E, Mercuri E, Rutherford M, et al. Combined use of electroencephalogram and magnetic resonance imaging in full-term neonates with acute encephalopathy. Pediatrics 2001; 107:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/71\">",
"      Pezzani C, Radvanyi-Bouvet MF, Relier JP, Monod N. Neonatal electroencephalography during the first twenty-four hours of life in full-term newborn infants. Neuropediatrics 1986; 17:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/72\">",
"      Pressler RM, Boylan GB, Morton M, et al. Early serial EEG in hypoxic ischaemic encephalopathy. Clin Neurophysiol 2001; 112:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/73\">",
"      van Rooij LG, Toet MC, Osredkar D, et al. Recovery of amplitude integrated electroencephalographic background patterns within 24 hours of perinatal asphyxia. Arch Dis Child Fetal Neonatal Ed 2005; 90:F245.",
"     </a>",
"    </li>",
"    <li>",
"     Volpe JJ. Hypoxic-ischemic encephalopathy: clinical aspects. In: Neurology of the Newborn, 5th, Volpe JJ (Ed), Saunders, Philadelphia 2008. p.400.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/75\">",
"      Yager JY, Armstrong EA, Black AM. Treatment of the term newborn with brain injury: simplicity as the mother of invention. Pediatr Neurol 2009; 40:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/76\">",
"      Tagin MA, Woolcott CG, Vincer MJ, et al. Hypothermia for neonatal hypoxic ischemic encephalopathy: an updated systematic review and meta-analysis. Arch Pediatr Adolesc Med 2012; 166:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/77\">",
"      Shankaran S, Laptook AR, Ehrenkranz RA, et al. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med 2005; 353:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/78\">",
"      Azzopardi DV, Strohm B, Edwards AD, et al. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med 2009; 361:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/79\">",
"      Simbruner G, Mittal RA, Rohlmann F, et al. Systemic hypothermia after neonatal encephalopathy: outcomes of neo.nEURO.network RCT. Pediatrics 2010; 126:e771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/80\">",
"      Jacobs SE, Morley CJ, Inder TE, et al. Whole-body hypothermia for term and near-term newborns with hypoxic-ischemic encephalopathy: a randomized controlled trial. Arch Pediatr Adolesc Med 2011; 165:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/81\">",
"      Zhou WH, Cheng GQ, Shao XM, et al. Selective head cooling with mild systemic hypothermia after neonatal hypoxic-ischemic encephalopathy: a multicenter randomized controlled trial in China. J Pediatr 2010; 157:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/82\">",
"      Gunn AJ, Gluckman PD, Gunn TR. Selective head cooling in newborn infants after perinatal asphyxia: a safety study. Pediatrics 1998; 102:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/83\">",
"      Shankaran S, Pappas A, McDonald SA, et al. Childhood outcomes after hypothermia for neonatal encephalopathy. N Engl J Med 2012; 366:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/84\">",
"      Wyatt JS, Gluckman PD, Liu PY, et al. Determinants of outcomes after head cooling for neonatal encephalopathy. Pediatrics 2007; 119:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/85\">",
"      Laptook A, Tyson J, Shankaran S, et al. Elevated temperature after hypoxic-ischemic encephalopathy: risk factor for adverse outcomes. Pediatrics 2008; 122:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/86\">",
"      Perlman M, Shah P. Time to adopt cooling for neonatal hypoxic-ischemic encephalopathy: response to a previous commentary. Pediatrics 2008; 121:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/87\">",
"      Azzopardi D, Strohm B, Edwards AD, et al. Treatment of asphyxiated newborns with moderate hypothermia in routine clinical practice: how cooling is managed in the UK outside a clinical trial. Arch Dis Child Fetal Neonatal Ed 2009; 94:F260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/88\">",
"      Kattwinkel J, Perlman JM, Aziz K, et al. Neonatal resuscitation: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Pediatrics 2010; 126:e1400.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinial Excellence. IPG347. Therapeutic hypothermia with intracorporeal temperature monitoring for hypoxic perinatal brain injury. file://publications.nice.org.uk/therapeutic-hypothermia-with-intracorporeal-temperature-monitoring-for-hypoxic-perinatal-brain-ipg347 (Accessed on November 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/90\">",
"      Perlman JM, Wyllie J, Kattwinkel J, et al. Neonatal resuscitation: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Pediatrics 2010; 126:e1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/91\">",
"      Takenouchi T, Iwata O, Nabetani M, Tamura M. Therapeutic hypothermia for neonatal encephalopathy: JSPNM &amp; MHLW Japan Working Group Practice Guidelines Consensus Statement from the Working Group on Therapeutic Hypothermia for Neonatal Encephalopathy, Ministry of Health, Labor and Welfare (MHLW), Japan, and Japan Society for Perinatal and Neonatal Medicine (JSPNM). Brain Dev 2012; 34:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/92\">",
"      Papile LA. Systemic hypothermia--a \"cool\" therapy for neonatal hypoxic-ischemic encephalopathy. N Engl J Med 2005; 353:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/93\">",
"      Higgins RD, Raju TN, Perlman J, et al. Hypothermia and perinatal asphyxia: executive summary of the National Institute of Child Health and Human Development workshop. J Pediatr 2006; 148:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/94\">",
"      Blackmon LR, Stark AR, American Academy of Pediatrics Committee on Fetus and Newborn. Hypothermia: a neuroprotective therapy for neonatal hypoxic-ischemic encephalopathy. Pediatrics 2006; 117:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/95\">",
"      Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 2000; 97:10526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/96\">",
"      Chang YS, Mu D, Wendland M, et al. Erythropoietin improves functional and histological outcome in neonatal stroke. Pediatr Res 2005; 58:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/97\">",
"      McPherson RJ, Demers EJ, Juul SE. Safety of high-dose recombinant erythropoietin in a neonatal rat model. Neonatology 2007; 91:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/98\">",
"      McPherson RJ, Juul SE. Erythropoietin for infants with hypoxic-ischemic encephalopathy. Curr Opin Pediatr 2010; 22:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/99\">",
"      Zhu C, Kang W, Xu F, et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics 2009; 124:e218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/100\">",
"      Tan WK, Williams CE, Gunn AJ, et al. Pretreatment with monosialoganglioside GM1 protects the brain of fetal sheep against hypoxic-ischemic injury without causing systemic compromise. Pediatr Res 1993; 34:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/24/2442/abstract/101\">",
"      Han BH, D'Costa A, Back SA, et al. BDNF blocks caspase-3 activation in neonatal hypoxia-ischemia. Neurobiol Dis 2000; 7:38.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6216 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_24_2442=[""].join("\n");
var outline_f2_24_2442=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8677534\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS AND NEONATAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Cranial sonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8678972\">",
"      - Head CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Head MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Electroencephalography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diagnosis of neonatal asphyxia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - ACOG criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Limitations of ACOG criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical predictors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neuroimaging predictors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      EEG predictors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Therapeutic hypothermia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Conclusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8678465\">",
"      Supportive management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Future prospects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8677534\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=related_link\">",
"      Approach to neuroimaging in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=related_link\">",
"      Epidemiology and etiology of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30953?source=related_link\">",
"      Etiology and pathogenesis of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25625?source=related_link\">",
"      Lumbar puncture: Indications, contraindications, technique, and complications in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/0/13?source=related_link\">",
"      Treatment of neonatal seizures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_24_2443="Kadish staging ONB";
var content_f2_24_2443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Kadish staging of olfactory neuroblastomas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Stage",
"      </td>",
"      <td class=\"subtitle1\">",
"       Definition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Confined to nasal cavity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       B",
"      </td>",
"      <td>",
"       Involves the nasal cavity and one or more paranasal sinuses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       C",
"      </td>",
"      <td>",
"       Extending beyond the nasal cavity or paranasal sinuses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       D",
"      </td>",
"      <td>",
"       Regional lymph node or distant metastasis",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Kadish, S, Goodman, M, Wang, CC, Cancer 1976; 37:1571.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_24_2443=[""].join("\n");
var outline_f2_24_2443=null;
var title_f2_24_2444="Fetal platelet count by GA";
var content_f2_24_2444=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Platelet count, 10",
"    <sup>",
"     9",
"    </sup>",
"    /L",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        GA",
"       </td>",
"       <td class=\"subtitle1\">",
"        5th percentile",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mean",
"       </td>",
"       <td class=\"subtitle1\">",
"        95th percentile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        145",
"       </td>",
"       <td>",
"        219",
"       </td>",
"       <td>",
"        293",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        148",
"       </td>",
"       <td>",
"        222",
"       </td>",
"       <td>",
"        297",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        151",
"       </td>",
"       <td>",
"        225",
"       </td>",
"       <td>",
"        300",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        154",
"       </td>",
"       <td>",
"        229",
"       </td>",
"       <td>",
"        303",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        157",
"       </td>",
"       <td>",
"        232",
"       </td>",
"       <td>",
"        306",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        160",
"       </td>",
"       <td>",
"        235",
"       </td>",
"       <td>",
"        310",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        163",
"       </td>",
"       <td>",
"        238",
"       </td>",
"       <td>",
"        313",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        166",
"       </td>",
"       <td>",
"        241",
"       </td>",
"       <td>",
"        316",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        169",
"       </td>",
"       <td>",
"        244",
"       </td>",
"       <td>",
"        319",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        172",
"       </td>",
"       <td>",
"        247",
"       </td>",
"       <td>",
"        323",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        175",
"       </td>",
"       <td>",
"        250",
"       </td>",
"       <td>",
"        326",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_24_2444=[""].join("\n");
var outline_f2_24_2444=null;
var title_f2_24_2445="Physical findings in ILD";
var content_f2_24_2445=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Extrapulmonary physical findings in the interstitial lung diseases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Physical findings",
"      </td>",
"      <td class=\"subtitle1\">",
"       Associated conditions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Systemic arterial hypertension",
"      </td>",
"      <td>",
"       Connective tissue disease; neurofibromatosis; some diffuse alveolar hemorrhage syndromes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"       Skin changes:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Erythema nodosum",
"      </td>",
"      <td class=\"sublist_other\">",
"       Sarcoidosis; connective tissue disease; Behcet's syndrome, histoplasmosis, coccidioidomycosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Maculopapular rash",
"      </td>",
"      <td class=\"sublist_other\">",
"       Drug-induced; amyloidosis; lipoidosis; connective tissue disease; Gaucher's disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Heliotrope rash",
"      </td>",
"      <td class=\"sublist_other\">",
"       Dermatomyositis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Telangiectasia",
"      </td>",
"      <td class=\"sublist_other\">",
"       Scleroderma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Raynaud's phenomenon",
"      </td>",
"      <td class=\"sublist_other\">",
"       Idiopathic pulmonary fibrosis; connective tissue disease (scleroderma)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cafe-au-lait spots",
"      </td>",
"      <td class=\"sublist_other\">",
"       Neurofibromatosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cutaneous vasculitis",
"      </td>",
"      <td class=\"sublist_other\">",
"       Systemic vasculitides; connective tissue disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Subcutaneous nodules",
"      </td>",
"      <td class=\"sublist_other\">",
"       Neurofibromatosis; rheumatoid arthritis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Albinism",
"      </td>",
"      <td class=\"sublist_other\">",
"       Hermansky-Pudlak syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Calcinosis",
"      </td>",
"      <td class=\"sublist_other\">",
"       Dermatomyositis; scleroderma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"       Eye changes:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Uveitis",
"      </td>",
"      <td class=\"sublist_other\">",
"       Sarcoidosis; Behcet's syndrome; ankylosing spondylitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Scleritis",
"      </td>",
"      <td class=\"sublist_other\">",
"       Systemic vasculitis; systemic lupus erythematosus; scleroderma; sarcoidosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Keratoconjunctivitis sicca",
"      </td>",
"      <td>",
"       Lymphocytic interstitial pneumonia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Salivary gland enlargement",
"      </td>",
"      <td>",
"       Sarcoidosis, lymphocytic interstitial pneumonia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Peripheral lymphadenopathy",
"      </td>",
"      <td>",
"       Sarcoidosis; lymphangitic carcinomatosis; lymphocytic interstitial pneumonia; lymphoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hepatosplenomegaly",
"      </td>",
"      <td>",
"       Sarcoidosis; pulmonary histiocytosis X; connective tissue disease; amyloidosis; lymphocytic interstitial pneumonia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pericarditis",
"      </td>",
"      <td>",
"       Radiation pneumonitis; connective tissue disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Myositis",
"      </td>",
"      <td>",
"       Connective tissue disease; drugs (L-tryptophan)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Muscle weakness",
"      </td>",
"      <td>",
"       Connective tissue disease",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Schwarz MI, King TE Jr, Cherniack RM. General principles and diagnostic approach to the interstitial lung diseases. In: Murray JF, Nadel JA, (Eds), Textbook of Respiratory Medicine, 2nd ed, Philadelphia, WB Saunders Co, 1994, pp. 1803-1826.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_24_2445=[""].join("\n");
var outline_f2_24_2445=null;
var title_f2_24_2446="Blunt trauma mechanism";
var content_f2_24_2446=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Blunt trauma mechanisms and associated injuries",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mechanism of injury",
"       </td>",
"       <td class=\"subtitle1\">",
"        Additional considerations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential associated injuries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Motor vehicle collisions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Head-on collision",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Facial injuries",
"        </p>",
"        <p>",
"         Lower extremity injuries",
"        </p>",
"        <p>",
"         Aortic injuries",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rear-end collision",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Hyperextension injuries of cervical spine",
"        </p>",
"        <p>",
"         Cervical spine fractures",
"        </p>",
"        <p>",
"         Central cord syndrome",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lateral (T-bone) collision",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Thoracic injuries",
"        </p>",
"        <p>",
"         Abdominal injuries: spleen, liver",
"        </p>",
"        <p>",
"         Pelvic injuries",
"        </p>",
"        <p>",
"         Clavicle, humerus, rib fractures",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rollover",
"       </td>",
"       <td>",
"        <p>",
"         Greater chance of ejection",
"        </p>",
"        <p>",
"         Significant mechanism of injury",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Crush injuries",
"        </p>",
"        <p>",
"         Compression fractures of spine",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ejected from vehicle",
"       </td>",
"       <td>",
"        <p>",
"         Likely unrestrained",
"        </p>",
"        <p>",
"         Significant mortality",
"        </p>",
"       </td>",
"       <td>",
"        Spinal injuries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Windshield damage",
"       </td>",
"       <td>",
"        Likely unrestrained",
"       </td>",
"       <td>",
"        <p>",
"         Closed head injuries, coup and countercoup injuries",
"        </p>",
"        <p>",
"         Facial fractures",
"        </p>",
"        <p>",
"         Skull fractures",
"        </p>",
"        <p>",
"         Cervical spine fractures",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Steering wheel damage",
"       </td>",
"       <td>",
"        Likely unrestrained",
"       </td>",
"       <td>",
"        Thoracic injuries",
"        <ul>",
"         <li>",
"          Sternal and rib fractures, flail chest",
"         </li>",
"         <li>",
"          Cardiac contusion",
"         </li>",
"         <li>",
"          Aortic injuries",
"         </li>",
"         <li>",
"          Hemo/pneumothoraces",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dashboard involvement/damage",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Pelvic and acetabular injuries",
"        </p>",
"        <p>",
"         Dislocated hip",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        Restraint/seat belt use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Proper three-point restraint",
"       </td>",
"       <td class=\"sublist_other\">",
"        Decreased morbidity",
"       </td>",
"       <td class=\"sublist_other\">",
"        Sternal and rib fractures, pulmonary contusions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Lap belt only",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        Chance fractures, abdominal injuries, head and facial injuries/fractures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Shoulder belt only",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        Cervical spine injuries/fractures, \"submarine\" out of restraint devices (possible ejection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Airbag deployment",
"       </td>",
"       <td>",
"        <p>",
"         Front-end collisions",
"        </p>",
"        <p>",
"         Less severe head/upper torso injuries",
"        </p>",
"        <p>",
"         Not effective for lateral impacts",
"        </p>",
"        <p>",
"         More severe injuries in children (improper front seat placement)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Upper extremity soft tissue injuries/fractures",
"        </p>",
"        <p>",
"         Lower extremity injuries/fractures",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Pedestrian versus automobile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Low speed (braking automobile)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Tibia and fibula fractures, knee injuries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        High speed",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Waddle's triad - tibia/fibula or femur fractures, truncal injuries, craniofacial injuries",
"        </p>",
"        <p>",
"         \"Thrown\" pedestrians at risk for multisystem injuries",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Bicycle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Automobile related",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Closed head injuries",
"        </p>",
"        \"Handlebar\" injuries",
"        <ul>",
"         <li>",
"          Spleen/liver lacerations",
"         </li>",
"         <li>",
"          Additional intra-abdominal injuries",
"         </li>",
"         <li>",
"          Consider penetrating injuries",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nonautomobile related",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Extremity injuries",
"        </p>",
"        <p>",
"         \"Handlebar\" injuries",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\">",
"        Falls",
"       </td>",
"       <td colspan=\"2\">",
"        LD",
"        <sub>",
"         50",
"        </sub>",
"        36 - 60 ft",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vertical impact",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Calcaneal and lower extremity fractures",
"        </p>",
"        <p>",
"         Pelvic fractures",
"        </p>",
"        <p>",
"         Closed head injuries",
"        </p>",
"        <p>",
"         Cervical spine fractures",
"        </p>",
"        <p>",
"         Renal and renal vascular injuries",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Horizontal impact",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Craniofacial fractures",
"        </p>",
"        <p>",
"         Hand and wrist fractures",
"        </p>",
"        <p>",
"         Abdominal and thoracic visceral injuries",
"        </p>",
"        <p>",
"         Aortic injuries",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Gross, E, Martel, M. Multiple trauma. In: Rosen's Emergency Medicine: Concepts and Clinical Practice, 7th ed., Marx, JA, Hockberger, RS, Walls, RM, et al. (Eds), Mosby Elsevier, Philadelphia 2010. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_24_2446=[""].join("\n");
var outline_f2_24_2446=null;
var title_f2_24_2447="Impetigo vesiculopustules";
var content_f2_24_2447=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Impetigo vesiculopustules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 213px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Impetigo vesiculopustules with crusting.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Larry M Baddour, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_24_2447=[""].join("\n");
var outline_f2_24_2447=null;
